US20200360355A1 - Enhancers of notch signaling and their use thereof in the treatment of cancers and malignancies medicable by upregulation of notch - Google Patents
Enhancers of notch signaling and their use thereof in the treatment of cancers and malignancies medicable by upregulation of notch Download PDFInfo
- Publication number
- US20200360355A1 US20200360355A1 US16/938,475 US202016938475A US2020360355A1 US 20200360355 A1 US20200360355 A1 US 20200360355A1 US 202016938475 A US202016938475 A US 202016938475A US 2020360355 A1 US2020360355 A1 US 2020360355A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- substituted
- unsubstituted
- branched
- linear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 34
- 102000005650 Notch Receptors Human genes 0.000 title claims description 89
- 108010070047 Notch Receptors Proteins 0.000 title claims description 89
- 238000011282 treatment Methods 0.000 title abstract description 22
- 230000011664 signaling Effects 0.000 title description 49
- 239000003623 enhancer Substances 0.000 title description 7
- 230000003827 upregulation Effects 0.000 title description 3
- 230000036210 malignancy Effects 0.000 title description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 46
- 150000003839 salts Chemical class 0.000 claims abstract description 34
- 201000010099 disease Diseases 0.000 claims abstract description 32
- 150000002148 esters Chemical class 0.000 claims abstract description 26
- 201000011510 cancer Diseases 0.000 claims abstract description 25
- 208000035475 disorder Diseases 0.000 claims abstract description 13
- 238000009169 immunotherapy Methods 0.000 claims abstract description 11
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 claims abstract description 10
- 201000010536 head and neck cancer Diseases 0.000 claims abstract description 10
- 208000014829 head and neck neoplasm Diseases 0.000 claims abstract description 10
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims abstract description 10
- 230000000955 neuroendocrine Effects 0.000 claims abstract description 10
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims abstract description 10
- 206010041823 squamous cell carcinoma Diseases 0.000 claims abstract description 10
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 9
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 9
- 208000024770 Thyroid neoplasm Diseases 0.000 claims abstract description 9
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 9
- 201000011519 neuroendocrine tumor Diseases 0.000 claims abstract description 9
- 230000008929 regeneration Effects 0.000 claims abstract description 9
- 238000011069 regeneration method Methods 0.000 claims abstract description 9
- 208000009621 actinic keratosis Diseases 0.000 claims abstract description 8
- 208000002458 carcinoid tumor Diseases 0.000 claims abstract description 8
- 230000001771 impaired effect Effects 0.000 claims abstract description 8
- 201000008261 skin carcinoma Diseases 0.000 claims abstract description 8
- 208000000649 small cell carcinoma Diseases 0.000 claims abstract description 8
- 208000021642 Muscular disease Diseases 0.000 claims abstract description 7
- 201000006938 muscular dystrophy Diseases 0.000 claims abstract description 7
- 208000020352 skin basal cell carcinoma Diseases 0.000 claims abstract description 6
- 125000001424 substituent group Chemical group 0.000 claims description 150
- 150000001875 compounds Chemical class 0.000 claims description 122
- 125000000217 alkyl group Chemical group 0.000 claims description 108
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 88
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 claims description 60
- 125000000304 alkynyl group Chemical group 0.000 claims description 59
- 125000003342 alkenyl group Chemical group 0.000 claims description 58
- 229910052801 chlorine Inorganic materials 0.000 claims description 58
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 58
- 229910052731 fluorine Inorganic materials 0.000 claims description 58
- 229910052794 bromium Inorganic materials 0.000 claims description 55
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 52
- 229910052740 iodine Inorganic materials 0.000 claims description 50
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 34
- -1 pyidazine Chemical compound 0.000 claims description 30
- 125000001033 ether group Chemical group 0.000 claims description 29
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 14
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims description 14
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 14
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 14
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 14
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 7
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 7
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 7
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 6
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 6
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 6
- 125000006538 C11 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 208000029549 Muscle injury Diseases 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000007781 signaling event Effects 0.000 claims description 4
- 230000009435 amidation Effects 0.000 claims description 3
- 238000007112 amidation reaction Methods 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 238000005886 esterification reaction Methods 0.000 claims description 2
- 150000002989 phenols Chemical class 0.000 claims description 2
- 208000014674 injury Diseases 0.000 abstract description 7
- 208000027418 Wounds and injury Diseases 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 22
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- 238000000746 purification Methods 0.000 description 22
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 235000019439 ethyl acetate Nutrition 0.000 description 17
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 16
- 238000004440 column chromatography Methods 0.000 description 14
- 230000002708 enhancing effect Effects 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 239000012043 crude product Substances 0.000 description 12
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 description 12
- 206010060862 Prostate cancer Diseases 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000003208 petroleum Substances 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 125000001931 aliphatic group Chemical group 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 0 C.CC.[1*]C1=CC=C(OC)C=C1.[2*][5*]C.[6*]C(C)=[Y] Chemical compound C.CC.[1*]C1=CC=C(OC)C=C1.[2*][5*]C.[6*]C(C)=[Y] 0.000 description 8
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 238000001953 recrystallisation Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102400000552 Notch 1 intracellular domain Human genes 0.000 description 5
- 101800001628 Notch 1 intracellular domain Proteins 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- ILDJJTQWIZLGPO-UHFFFAOYSA-N ethyl 6-chloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=C(Cl)N=C1 ILDJJTQWIZLGPO-UHFFFAOYSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 201000001514 prostate carcinoma Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 102000001756 Notch2 Receptor Human genes 0.000 description 4
- 108010029751 Notch2 Receptor Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- JHRYZSFFDSNTFK-UHFFFAOYSA-N ethyl 4-[4-(2-methylbutan-2-yl)phenoxy]benzoate Chemical compound CCOC(=O)c1ccc(Oc2ccc(cc2)C(C)(C)CC)cc1 JHRYZSFFDSNTFK-UHFFFAOYSA-N 0.000 description 4
- UMPRJGKLMUDRHL-UHFFFAOYSA-N ethyl 4-fluorobenzoate Chemical compound CCOC(=O)C1=CC=C(F)C=C1 UMPRJGKLMUDRHL-UHFFFAOYSA-N 0.000 description 4
- SQPCLTFAPILWSV-UHFFFAOYSA-N ethyl 6-(4-tert-butylphenoxy)pyridine-3-carboxylate Chemical compound CCOC(=O)c1ccc(Oc2ccc(cc2)C(C)(C)C)nc1 SQPCLTFAPILWSV-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000003468 luciferase reporter gene assay Methods 0.000 description 4
- 210000003826 marginal zone b cell Anatomy 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 125000005650 substituted phenylene group Chemical group 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 229960003604 testosterone Drugs 0.000 description 4
- PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical class OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 3
- PJFFIQGITXYINH-UHFFFAOYSA-N 4-(4-cyclohexylphenoxy)benzoic acid Chemical compound OC(=O)c1ccc(Oc2ccc(cc2)C2CCCCC2)cc1 PJFFIQGITXYINH-UHFFFAOYSA-N 0.000 description 3
- PMXQUDMXXBCKJX-UHFFFAOYSA-N 4-(4-tert-butylphenoxy)-3-fluorobenzoic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1OC1=CC=C(C(O)=O)C=C1F PMXQUDMXXBCKJX-UHFFFAOYSA-N 0.000 description 3
- QHPQWRBYOIRBIT-UHFFFAOYSA-N 4-tert-butylphenol Chemical compound CC(C)(C)C1=CC=C(O)C=C1 QHPQWRBYOIRBIT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 3
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- CEWMOBOQZUGRST-UHFFFAOYSA-N ethyl 4-(4-cyclohexylphenoxy)benzoate Chemical compound C1(CCCCC1)C1=CC=C(OC2=CC=C(C(=O)OCC)C=C2)C=C1 CEWMOBOQZUGRST-UHFFFAOYSA-N 0.000 description 3
- TYHCXSPSEMKGGM-UHFFFAOYSA-N ethyl 4-(4-tert-butylphenoxy)-3-fluorobenzoate Chemical compound C(C)(C)(C)C1=CC=C(OC2=C(C=C(C(=O)OCC)C=C2)F)C=C1 TYHCXSPSEMKGGM-UHFFFAOYSA-N 0.000 description 3
- DPXOEJJGSCVNAB-UHFFFAOYSA-N ethyl 4-(4-tert-butylphenoxy)benzoate Chemical compound C(C)(C)(C)C1=CC=C(OC2=CC=C(C(=O)OCC)C=C2)C=C1 DPXOEJJGSCVNAB-UHFFFAOYSA-N 0.000 description 3
- AUJCOGJLGDJDFJ-UHFFFAOYSA-N ethyl 6-(4-cyclohexylphenoxy)pyridine-3-carboxylate Chemical compound C1(CCCCC1)C1=CC=C(OC2=NC=C(C(=O)OCC)C=C2)C=C1 AUJCOGJLGDJDFJ-UHFFFAOYSA-N 0.000 description 3
- LGAHUJFEEORPTR-UHFFFAOYSA-N ethyl 6-(4-tert-butyl-2-methylphenoxy)pyridine-3-carboxylate Chemical compound CCOC(=O)c1ccc(Oc2ccc(cc2C)C(C)(C)C)nc1 LGAHUJFEEORPTR-UHFFFAOYSA-N 0.000 description 3
- MHWUVKFCAYFRAL-UHFFFAOYSA-N ethyl 6-[4-(2-methylbutan-2-yl)phenoxy]pyridine-3-carboxylate Chemical compound CCOC(=O)c1ccc(Oc2ccc(cc2)C(C)(C)CC)nc1 MHWUVKFCAYFRAL-UHFFFAOYSA-N 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- UQGVRGHSAYWFRY-UHFFFAOYSA-N 4-(4-tert-butylphenoxy)benzoic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1OC1=CC=C(C(O)=O)C=C1 UQGVRGHSAYWFRY-UHFFFAOYSA-N 0.000 description 2
- NUKQFQZBQLLZAJ-UHFFFAOYSA-N 4-[4-(2-methylbutan-2-yl)phenoxy]benzoic acid Chemical compound C1=CC(C(C)(C)CC)=CC=C1OC1=CC=C(C(O)=O)C=C1 NUKQFQZBQLLZAJ-UHFFFAOYSA-N 0.000 description 2
- OAHMVZYHIJQTQC-UHFFFAOYSA-N 4-cyclohexylphenol Chemical compound C1=CC(O)=CC=C1C1CCCCC1 OAHMVZYHIJQTQC-UHFFFAOYSA-N 0.000 description 2
- JBLHKBHEBZTJEN-UHFFFAOYSA-N 6-(4-cyclohexylphenoxy)pyridine-3-carboxylic acid Chemical compound C1(CCCCC1)C1=CC=C(OC2=NC=C(C(=O)O)C=C2)C=C1 JBLHKBHEBZTJEN-UHFFFAOYSA-N 0.000 description 2
- XSWTUTFLIBBLAQ-UHFFFAOYSA-N 6-(4-tert-butyl-2-methylphenoxy)pyridine-3-carboxylic acid Chemical compound CC1=CC(C(C)(C)C)=CC=C1OC1=CC=C(C(O)=O)C=N1 XSWTUTFLIBBLAQ-UHFFFAOYSA-N 0.000 description 2
- WHIWGRCYMQLLAO-UHFFFAOYSA-N 6-(4-tert-butylphenoxy)pyridin-3-amine Chemical compound C1=CC(C(C)(C)C)=CC=C1OC1=CC=C(N)C=N1 WHIWGRCYMQLLAO-UHFFFAOYSA-N 0.000 description 2
- MMTUOOHPVFBBFP-UHFFFAOYSA-N 6-(4-tert-butylphenoxy)pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1OC1=CC=C(C(N)=O)C=N1 MMTUOOHPVFBBFP-UHFFFAOYSA-N 0.000 description 2
- PFDJDBDZWDCYLY-UHFFFAOYSA-N 6-(4-tert-butylphenoxy)pyridine-3-carboxylic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1OC1=CC=C(C(O)=O)C=N1 PFDJDBDZWDCYLY-UHFFFAOYSA-N 0.000 description 2
- LTEOINYXBFJBCZ-UHFFFAOYSA-N 6-[4-(2-methylbutan-2-yl)phenoxy]pyridine-3-carboxylic acid Chemical compound C1=CC(C(C)(C)CC)=CC=C1OC1=CC=C(C(O)=O)C=N1 LTEOINYXBFJBCZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102100039673 Disintegrin and metalloproteinase domain-containing protein 10 Human genes 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 102000001759 Notch1 Receptor Human genes 0.000 description 2
- 108010029755 Notch1 Receptor Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 229940123934 Reductase inhibitor Drugs 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 208000033781 Thyroid carcinoma Diseases 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004900 c-terminal fragment Anatomy 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- DXTJABDRJMWOFB-UHFFFAOYSA-N ethyl 6-(4-methylphenoxy)pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OCC)=CC=C1OC1=CC=C(C)C=C1 DXTJABDRJMWOFB-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 102000007236 involucrin Human genes 0.000 description 2
- 108010033564 involucrin Proteins 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- NRZWYNLTFLDQQX-UHFFFAOYSA-N p-tert-Amylphenol Chemical compound CCC(C)(C)C1=CC=C(O)C=C1 NRZWYNLTFLDQQX-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000002100 tumorsuppressive effect Effects 0.000 description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UUZJJNBYJDFQHL-UHFFFAOYSA-N 1,2,3-triazolidine Chemical compound C1CNNN1 UUZJJNBYJDFQHL-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- DWVJASHDNJMDNH-UHFFFAOYSA-N 1-[[4-ethyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]thiophen-2-yl]methyl]azetidine-3-carboxylic acid Chemical compound S1C(C=2N=C(ON=2)C=2C=CC(OC=3C=CC=CC=3)=CC=2)=C(CC)C=C1CN1CC(C(O)=O)C1 DWVJASHDNJMDNH-UHFFFAOYSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- CQGAXJGXGLVFGJ-UHFFFAOYSA-N 2-phenoxypyridine-3-carboxylic acid Chemical class OC(=O)C1=CC=CN=C1OC1=CC=CC=C1 CQGAXJGXGLVFGJ-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- GUUULVAMQJLDSY-UHFFFAOYSA-N 4,5-dihydro-1,2-thiazole Chemical compound C1CC=NS1 GUUULVAMQJLDSY-UHFFFAOYSA-N 0.000 description 1
- WEDKTMOIKOKBSH-UHFFFAOYSA-N 4,5-dihydrothiadiazole Chemical compound C1CN=NS1 WEDKTMOIKOKBSH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SNKLPZOJLXDZCW-UHFFFAOYSA-N 4-tert-butyl-2-methylphenol Chemical compound CC1=CC(C(C)(C)C)=CC=C1O SNKLPZOJLXDZCW-UHFFFAOYSA-N 0.000 description 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 1
- 108091007504 ADAM10 Proteins 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 238000011814 C57BL/6N mouse Methods 0.000 description 1
- FYAJYSXYGIZMTF-UHFFFAOYSA-N CC(C)(C)C1=CC=C(OC2=CC=C(C(=O)O)C=C2)C=C1.CC(C)(C)C1=CC=C(OC2=NC=C(C(N)=O)C=C2)C=C1 Chemical compound CC(C)(C)C1=CC=C(OC2=CC=C(C(=O)O)C=C2)C=C1.CC(C)(C)C1=CC=C(OC2=NC=C(C(N)=O)C=C2)C=C1 FYAJYSXYGIZMTF-UHFFFAOYSA-N 0.000 description 1
- QXBXZVGXKKLXDI-UHFFFAOYSA-N CC(C)(C)C1=CC=C(OC2=CC=C(C(=O)O)C=C2F)C=C1.CC1=C(OC2=NC=C(C(=O)O)C=C2)C=CC(C(C)(C)C)=C1.CCOC(=O)C1=CC=C(OC2=CC=C(C(C)(C)C)C=C2)C(F)=C1.CCOC(=O)C1=CC=C(OC2=CC=C(C(C)(C)CC)C=C2)C=C1.CCOC(=O)C1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1.CCOC(=O)C1=CN=C(OC2=CC=C(C)C=C2)C=C1 Chemical compound CC(C)(C)C1=CC=C(OC2=CC=C(C(=O)O)C=C2F)C=C1.CC1=C(OC2=NC=C(C(=O)O)C=C2)C=CC(C(C)(C)C)=C1.CCOC(=O)C1=CC=C(OC2=CC=C(C(C)(C)C)C=C2)C(F)=C1.CCOC(=O)C1=CC=C(OC2=CC=C(C(C)(C)CC)C=C2)C=C1.CCOC(=O)C1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1.CCOC(=O)C1=CN=C(OC2=CC=C(C)C=C2)C=C1 QXBXZVGXKKLXDI-UHFFFAOYSA-N 0.000 description 1
- LVNBYLKNSDBIIH-UHFFFAOYSA-N CC(C)(C)C1=CC=C(OC2=NC=C(C(=O)O)C=C2)C=C1.CCC(C)(C)C1=CC=C(OC2=NC=C(C(=O)O)C=C2)C=C1.CCOC(=O)C1=CC=C(OC2=CC=C(C(C)(C)C)C=C2)C=C1.CCOC(=O)C1=CN=C(OC2=CC=C(C(C)(C)C)C=C2)C=C1.CCOC(=O)C1=CN=C(OC2=CC=C(C(C)(C)CC)C=C2)C=C1.CCOC(=O)C1=CN=C(OC2=CC=C(C3CCCCC3)C=C2)C=C1.O=C(O)C1=CN=C(OC2=CC=C(C3CCCCC3)C=C2)C=C1 Chemical compound CC(C)(C)C1=CC=C(OC2=NC=C(C(=O)O)C=C2)C=C1.CCC(C)(C)C1=CC=C(OC2=NC=C(C(=O)O)C=C2)C=C1.CCOC(=O)C1=CC=C(OC2=CC=C(C(C)(C)C)C=C2)C=C1.CCOC(=O)C1=CN=C(OC2=CC=C(C(C)(C)C)C=C2)C=C1.CCOC(=O)C1=CN=C(OC2=CC=C(C(C)(C)CC)C=C2)C=C1.CCOC(=O)C1=CN=C(OC2=CC=C(C3CCCCC3)C=C2)C=C1.O=C(O)C1=CN=C(OC2=CC=C(C3CCCCC3)C=C2)C=C1 LVNBYLKNSDBIIH-UHFFFAOYSA-N 0.000 description 1
- QPOLSVCEXYRFLX-UHFFFAOYSA-N CCC(C)(C)C1=CC=C(OC2=CC=C(C(=O)O)C=C2)C=C1.CCOC(=O)C1=CC=C(OC2=CC=C(C3CCCCC3)C=C2)C=C1.O=C(O)C1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1.O=C(O)C1=CC=C(OC2=CC=C(C3CCCCC3)C=C2)C=C1 Chemical compound CCC(C)(C)C1=CC=C(OC2=CC=C(C(=O)O)C=C2)C=C1.CCOC(=O)C1=CC=C(OC2=CC=C(C3CCCCC3)C=C2)C=C1.O=C(O)C1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1.O=C(O)C1=CC=C(OC2=CC=C(C3CCCCC3)C=C2)C=C1 QPOLSVCEXYRFLX-UHFFFAOYSA-N 0.000 description 1
- XVJIWIRPTYKNGA-UHFFFAOYSA-N CCOC(=O)C1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1 Chemical compound CCOC(=O)C1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1 XVJIWIRPTYKNGA-UHFFFAOYSA-N 0.000 description 1
- 101100378457 Caenorhabditis elegans sup-17 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 241000854350 Enicospilus group Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 230000005913 Notch signaling pathway Effects 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- NHSRNYTWPHUGCO-UHFFFAOYSA-N O=C(O)C1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1 Chemical compound O=C(O)C1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1 NHSRNYTWPHUGCO-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 229940121773 Secretase inhibitor Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000480 butynyl group Chemical class [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- QHFQAJHNDKBRBO-UHFFFAOYSA-L calcium chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ca+2] QHFQAJHNDKBRBO-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940043370 chrysin Drugs 0.000 description 1
- 235000015838 chrysin Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000011977 dual antiplatelet therapy Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- NKIWNSXGZXESSM-UHFFFAOYSA-N ethyl 3,4-difluorobenzoate Chemical compound CCOC(=O)C1=CC=C(F)C(F)=C1 NKIWNSXGZXESSM-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 231100000302 myotoxic Toxicity 0.000 description 1
- 230000003630 myotoxic effect Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical class [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical class 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- IZJDOKYDEWTZSO-UHFFFAOYSA-N phenethyl isothiocyanate Chemical compound S=C=NCCC1=CC=CC=C1 IZJDOKYDEWTZSO-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- ZYXWYDDFNXBTFO-UHFFFAOYSA-N tetrazolidine Chemical compound C1NNNN1 ZYXWYDDFNXBTFO-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- RLTPJVKHGBFGQA-UHFFFAOYSA-N thiadiazolidine Chemical compound C1CSNN1 RLTPJVKHGBFGQA-UHFFFAOYSA-N 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000005300 thiocarboxy group Chemical group C(=S)(O)* 0.000 description 1
- AWIJRPNMLHPLNC-UHFFFAOYSA-N thiocarboxylic acid group Chemical group C(=S)O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Definitions
- the present invention relates to compounds which are enhancers of Notch signaling and lend themselves for the treatment of Notch-associated malignancies, such as cancer, degenerative muscle diseases, skin diseases like psoriasis and atopic dermatitis, and immunological disorders, as well as for the use in immunotherapy for cancer.
- Notch signaling represents a short-range intercellular signaling pathway that plays a critical role during embryogenesis and adult tissue homeostasis. Depending on the cellular context, Notch signaling is involved in the regulation of cell fate determination, differentiation, apoptosis and proliferation, but also in stem cell maintenance. Presence and intensity of Notch signaling in the cellular frame are temporally and spatially strictly controlled. In consequence, abnormal Notch activity can lead to various disease situations. Although Notch was historically identified as an oncogene. studies within the last decade have also demonstrated the tumor suppressive effects of Notch signaling (Koch and Radtke, 2010) (South et al., 2012).
- Notch functions as a tumor suppressor.
- cancers including but not limited to cutaneous and lung squamous cell carcinoma (Wang et al., 2011), head and neck cancer (Agrawal et al., 2011; Stransky et al., 2011), neuroendocrine tumors such as thyroid carcinoma (Yu et al., 2013), or neuroendocrine small cell carcinoma (Sriuranpong et al., 2001) and carcinoid tumors (Greenblatt et al., 2007) will induce differentiation and block growth of cancer cells.
- the present invention comprises for use a family of small molecules capable to enhance Notch signaling, resulting in the potential applications, which will be disclosed in the application.
- the applications are implementable in both human and veterinary medicine.
- WO2013/093885 discloses 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine and derivatives thereof having Notch signalling pathway inhibition properties for the treatment and/or prevention of cancer, wherein the cancer is a Notch dependent cancer, and wherein the Notch dependent cancer is preferably selected from the group comprising T cell-Acute lymphoblastic leukemia (T-ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), breast cancer, pancreatic cancer, prostate cancer, melanoma, brain tumors, tumor angiogenesis, and colorectal cancer.
- T-ALL T cell-Acute lymphoblastic leukemia
- CML chronic myeloid leukemia
- CLL chronic lymphocytic leukemia
- MCL mantle cell lymphoma
- breast cancer pancreatic cancer
- prostate cancer melanoma
- brain tumors tumor angiogenesis
- colorectal cancer
- Notch signaling comprises the use of activating Notch ligand-mimicking peptides as for instance a JAG-1 protein peptide fragment (B. J. Nickoloff, Cell Death and Differentiation 2002, 9, 842-855). Nonetheless, this tool to trigger Notch signaling is still in development and only available for research yet.
- Notch signaling enhancers that can be used to treat and prevent Notch-associated diseases, preferably dermatologic diseases, immunological disorders, muscular diseases e.g. muscular dystrophy and impaired regeneration capacity after injury, and cancer, e.g. squamous cell carcinoma, neuroendocrine tumors, thyroid carcinomas and others, as well as for immunotherapy against cancer.
- dermatologic diseases e.g. dermatologic diseases, immunological disorders, muscular diseases e.g. muscular dystrophy and impaired regeneration capacity after injury
- cancer e.g. squamous cell carcinoma, neuroendocrine tumors, thyroid carcinomas and others, as well as for immunotherapy against cancer.
- one object underlying the present invention is to provide compounds acting as Notch signaling enhancers and which can be used to treat cancers and other diseases which cannot be treated by Notch signaling inhibitors, or provide compounds which render possible an alternative treatment to Notch signaling inhibitors, of the respective diseases.
- the diseases and cancers are in particular the cancers cited in WO 2013/093885.
- a further object underlying the present invention is to provide compounds acting as Notch signaling enhancers, are possible to treat the above-cited diseases and which preferably do not show the drawbacks of the known compounds.
- the present invention relates to the use for enhancing Notch signaling in an individual, of a compound showing the general formula (I)
- X is an aromatic cycle selected from a phenylene ring C 6 H 4 , in which one or more H atoms are optionally replaced independently by one or more of the substituents Z; or X is a 6-membered aromatic heterocycle containing 1 or 2 N atoms, in which one or more H atoms are optionally replaced independently by one or more of the substituents Z;
- R 1 is selected from: H; linear and branched, unsubstituted and substituted C 1 -C 16 alkyl; linear and branched, unsubstituted and substituted C 2 -C 8 alkenyl; linear and branched, unsubstituted and substituted C 2 -C 8 alkynyl; substituted and unsubstituted C 3 -C 8 cycloalkyl; substituted and unsubstituted C 5 -C 8 cycloalkenyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl and norbornyl groups are selected from the group F, Cl, Br, I, —CN, —NCO, —NCS, N 3 , and wherein the named groups can be single or multiple substituted;
- R 2 -R 5 are independently of each other selected from: H, F, Cl, Br, I; linear and branched, unsubstituted and substituted C 1 -C 4 alkyl, C 2 -C 4 alkenyl and C 2 -C 4 alkynyl, cyclopropyl and cyclobutyl, and wherein the substituents of the named alkyl, alkenyl, alkynyl, cyclopropyl and cyclobutyl groups are selected from F, Cl, Br and I;
- Y is O or S
- Z is selected from: F, Cl, Br, I, linear and branched, unsubstituted and substituted C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, cyclopropyl and cyclobutyl, and wherein the substituents of the named alkyl, alkenyl, alkynyl, cyclopropyl and cyclobutyl groups can be selected from F, Cl, Br and I;
- R 6 is selected from: OR 7 , NR 8 R 9 , NHOH;
- R 7 is selected from H and linear and branched C 1 -C 6 alkyl
- R 8 and R 9 are independently of each other selected from H and linear and branched C 1 -C 6 alkyl
- substituted as used herein includes both part and full substitution.
- R 1 is selected from linear and branched, unsubstituted and substituted C 4 -C 16 alkyl; linear and branched, substituted and unsubstituted C 4 -C 8 alkenyl; linear and branched, unsubstituted and substituted C 4 -C 8 alkynyl; substituted and unsubstituted C 4 -C 8 cycloalkyl; substituted and unsubstituted C 5 -C 8 cycloalkenyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl and norbornyl groups are selected from the group F, Cl, Br, I, —CN, —NCO, —NCS, N 3 , and wherein the named groups can be single or multiple substituted;
- the phenylene ring X is not substituted, or monosubstituted (i.e. contains 0 or 1 substituent Z other than H);
- the phenylene ring X is not substituted by F, Cl, Br or I (substituent Z) in position 2 and 6 with respect to the ether group (position o and o′); and/or
- the phenylene ring X is not substituted by —CH 3 , —C 2 H 5 , C 3 H 7 and/or C 4 H 9 (substituent Z) in position 2 and 6 with respect to the ether group (position o and o′);
- the phenylene ring X is not substituted by —CH 3 , —C 2 H 5 , C 3 H 7 and/or C 4 H 9 .
- inventions cited above within the most general embodiment also comprise the combination of embodiment A with each of the embodiments B1, B2, B3, B4, B5, B6, B7 and B8.
- R 1 is a higher noncyclic or cyclic aliphatic group, starting from C 4 , i.e. if R 1 is a group selected from those which have been cited beforehand within the embodiments A.
- alkyl refers to an aliphatic saturated hydrocarbon group, including methyl (C 1 alkyl), ethyl (C 2 alkyl), n-propyl, iso-propyl (C 3 alkyl), n-butyl, iso-butyl, sec.-butyl and tert.-butyl (C 4 alkyl), n-pentyl (amyl), 2-pentyl (sec-pentyl), 3-pentyl; 2-methylbutyl, 3-methylbutyl (iso-pentyl or iso-amyl), 3-methylbut-2-yl, 2-methylbut-2-yl; 2,2-dimethylpropyl (neopentyl) (C 5 alkyl), a hexyl group (C 5 alkyl) including all isomers, a heptyl group (C 7 alkyl) including all isomers, an octyl group (C 8 alkyl) including all is
- alkenyl refers to an aliphatic unsaturated hydrocarbon group, including ethenyl (C 2 alkenyl), n-propenyl, iso-propenyl (C 3 alkenyl), n-butenyl, iso-butenyl, sec.-butenyl and tert.-butenyl (C 4 alkenyl), a pentenyl group including all isomers (C 5 alkenyl), a hexenyl group (C 6 alkenyl) including all isomers, a heptenyl group including all isomers (C, alkenyl), an octenyl group including all isomers (C 8 alkenyl), as known to the person skilled in the art.
- alkynyl refers to the above cited C 2 -C 8 groups having a double bond, but having a triple bond and which are known to the person skilled in the art. Examples include ethynyl (C 2 alkynyl), n-propynyl and iso-propynyl (C 3 alkynyl), the various isomers of butynyl (C 4 alkynyl), the various isomers of pentynyl (C 5 alkynyl), the various isomers of hexynyl (C 6 alkynyl), the various isomers of heptynyl (C 7 alkynyl), and the various isomers of octynyl (C 8 alkynyl).
- Cycloalkyl or “cycloalkyl ring” means an aliphatic cyclic saturated alkyl group, e.g. cyclopropyl (C 3 cycloalkyl), cyclobutyl (C 4 cycloalkyl), cyclopentyl (C 5 cycloalkyl), cyclohexyl (C 6 cycloalkyl), cycloheptyl (C 7 cycloalkyl), cyclooctyl (C 8 cycloalkyl).
- Each hydrogen of a cycloalkyl carbon may be replaced by a substituent.
- Cycloalkenyl or “cycloalkenyl ring” means a cyclic unsaturated (one or more double carbon-carbon bonds) aliphatic or aromatic group, e.g. cyclopropenyl (C 3 cycloalkenyl), cyclobutenyl (C 4 cycloalkenyl), cyclopentenyl (C 5 cycloalkenyl), cyclohexenyl (C 6 cycloalkenyl), cycloheptenyl (C 7 cycloalkenyl), cyclooctenyl (C 8 cycloalkenyl).
- Each hydrogen of a cycloalkyl carbon may be replaced by a substituent.
- R 2 , R 3 , R 4 and R 5 in case these are not H can be in the positions 2, 3, 5 and 6 with respect to the ether group.
- all R 2 , R 3 , R 4 and R 5 are H, or 1 or 2 of R 2 , R 3 , R 4 and R 5 are not H, but selected from the substituents defined above.
- the term “R 2 -R 5 are independently of each other selected from . . . ” as used throughout the present application means that 1, 2, 3 or 4 of R 2 , R 3 , R 4 and R 5 are other than H, and that each of R 2 , R 3 , R 4 and R 5 can have any of the meanings defined for the respective embodiment.
- the carbonyl derived group —C(Y)R 6 connected to the aromatic ring can be in position 2, 3 or 4 with respect to the ether bridge, preferably in position 4. This also applies with respect to formula (Ia), which in a preferred embodiment is a phenoxybenzoic acid derivative where the group —C(Y)R 6 is in position 4 with respect to the ether bridge (p-position).
- the substituent Z can be in the positions 2, 3, 4, 5 and 6 with respect to the ether group.
- 6-membered aromatic heterocycle containing 1 or 2 N atoms refers to a heterocycle containing either 1 N atom or 2 N atoms.
- This heterocycle is selected from pyridine, pyridazine, pyrimidine and pyrazine.
- the aromatic heterocycle is connected to O in the ether bridge via a chemical bond, and to the carbonyl derived group in another position of the heterocycle, meaning that at least two H atoms in the aromatic heterocycle are replaced by a chemical bond.
- H atoms for example 1, 2, 3 or 4, preferably 1 H atom, may be replaced by the group Z.
- the Notch signaling enhancing compound belongs to the family of phenoxybenzoic acids and phenoxynicotinic acids and derivatives thereof.
- the person skilled in the art is aware of appropriate derivates.
- Known examples include esters and amides.
- the invention relates to the compounds as defined in connection with formula (I) and/or a pharmaceutically acceptable salt or ester thereof, including all preferred, more preferred, even more preferred, first most preferred and second most preferred embodiments for the treatment of a disease associated with reduced Notch signaling activity.
- X is an aromatic cycle selected from a phenylene ring C 6 H 4 , in which one or more H atoms are optionally replaced independently by one or more of the substituents Z; or X is a 6-membered aromatic heterocycle containing 1 or 2 N atoms, in which one or more H atoms are optionally replaced independently by one or more of the substituents Z;
- R 1 is selected from: H; linear and branched, unsubstituted and substituted C 1 -C 12 alkyl; linear and branched, unsubstituted and substituted C 2 -C 8 alkenyl; linear and branched, unsubstituted and substituted C 2 -C 8 alkynyl; substituted and unsubstituted C 3 -C 8 cycloalkyl; substituted and unsubstituted C 5 -C 8 cycloalkenyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl and norbornyl groups are selected from the group F, Cl, Br, I, —CN, —NCO, —NCS, N 3 , and wherein the named groups can be single or multiple substituted (i.e. in case the named groups are substituted, they
- R 2 -R 5 are independently of each other selected from: H, F, Cl, Br, I; unsubstituted and substituted C 1 -C 2 alkyl, C 2 -alkenyl, C 2 -alkynyl, and wherein the named alkyl, alkenyl, and alkynyl groups can be substituted by F (i.e. in case the named groups are substituted, the substituent is F).
- Y is O or S
- Z is selected from F, Cl, Br, I; unsubstituted and substituted C 1 -C 2 alkyl, C 2 -alkenyl, C 2 -alkynyl, and wherein the substituent of the named alkyl, alkenyl and alkynyl groups can be F (i.e. in case the named groups are substituted, the substituent is F);
- R 6 is selected from: OR 7 , NR 8 R 9 , NHOH;
- R 7 is selected from H and linear and branched C 1 -C 4 alkyl
- R 1 , R 2 -R 5 and Z is a substituent other than H
- R 8 and R 9 are independently of each other selected from H and linear and branched C 1 -C 4 alkyl.
- R 1 is selected from linear and branched, unsubstituted and substituted C 4 -C 12 alkyl; linear and branched, substituted and unsubstituted C 4 -C 8 alkenyl; linear and branched, unsubstituted and substituted C 4 -C 8 alkynyl; substituted and unsubstituted C 4 -C 8 cycloalkyl; substituted and unsubstituted C 5 -C 8 cycloalkenyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl and norbornyl groups are selected from the group F, Cl, Br, I, —CN, —NCO, —NCS, N 3 , and wherein the named groups can be single or multiple substituted;
- the phenylene ring X is not substituted, or monosubstituted (i.e. contains 0 or 1 substituent Z other than H);
- the phenylene ring X is not substituted by F, Cl, Br or I (substituent Z) in position 2 and 6 with respect to the ether group (position o and o′); and/or
- the phenylene ring X is not substituted by —CH 3 , —C 2 H 5 , C 3 H 7 and/or C 4 H 9 (substituent Z) in position 2 and 6 with respect to the ether group (position o and o′);
- B8 the phenylene ring Xis not substituted by —CH 3 , —C 2 H 5 , C 3 H 7 and/or C 4 H 9 .
- the preferred embodimemts cited above within the above defined preferred embodiment also comprise the combination of embodiment A with each of the embodiments B1, B2, B3, B4, B5, B6, B7 and B8.
- R 1 is a higher noncyclic or cyclic aliphatic group, starting from C 4 , i.e. if R 1 is a group selected from those which have been cited beforehand within the embodiments A.
- X is an aromatic cycle selected from a phenylene ring C 6 H 4 , in which one or more H atoms are optionally replaced independently by one or more of the substituents Z; or X is a 6-membered aromatic heterocycle containing 1 or 2 N atoms, in which one or more H atoms are optionally replaced independently by one or more of the substituents Z;
- R 1 is selected from: H; linear and branched, unsubstituted and substituted C 1 -C 8 alkyl; linear and branched, unsubstituted and substituted C 2 -C 6 alkenyl; linear and branched, unsubstituted and substituted C 2 -C 6 alkynyl; substituted and unsubstituted C 3 -C 6 cycloalkyl; substituted and unsubstituted C 5 -C 6 cycloalkenyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl and norbornyl groups are selected from the group F, Cl, Br, I, —CN, —NCO, —NCS, N 3 , and wherein the named groups can be single or multiple substituted (i.e. in case the named groups are substituted, they
- R 2 -R 6 are independently of each other selected from: H, F, Cl, Br, I; unsubstituted and substituted C 1 -C 2 alkyl, C 2 -alkenyl, and C 2 -alkynyl, and wherein the substituents of the named alkyl, alkenyl and alkynyl groups can be F (i.e. in case the named groups are substituted, the substituent is F);
- Y is O or S
- Z is selected from F, Cl, Br, I; unsubstituted and substituted C 1 -C 2 alkyl C 2 -alkenyl, and C 2 -alkynyl, and wherein the substituents of the named alkyl, alkenyl and alkynyl groups can be F (i.e. in case the named groups are substituted, the substituent is F);
- R 6 is selected from: OR 7 , NR 8 R 9 , NHOH;
- R 7 is selected from H and linear and branched C 1 -C 4 alkyl
- R 8 and R 9 are independently of each other selected from H and linear and branched C 1 -C 4 alkyl.
- R 1 is selected from linear and branched, unsubstituted and substituted C 4 -C 8 alkyl; linear and branched, substituted and unsubstituted C 4 -C 6 alkenyl; linear and branched, unsubstituted and substituted C 4 -C 6 alkynyl; substituted and unsubstituted C 4 -C 6 cycloalkyl; substituted and unsubstituted C 5 -C 6 cycloalkenyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl and norbornyl groups are selected from the group F, Cl, Br, I, —CN, —NCO, —NCS, N 3 , and wherein the named groups can be single or multiple substituted (i.e. in case the named groups are substituted, they carry one,
- the phenylene ring X is not substituted, or monosubstituted (i.e. contains 0 or 1 substituent Z other than H);
- the phenylene ring X is not substituted by F, Cl, Br or I (substituent Z) in position 2 and 6 with respect to the ether group (position o and o′); and/or
- the phenylene ring X is not substituted by —CH 3 , —C 2 H 5 , C 3 H 7 and/or C 4 H 9 (substituent Z) in position 2 and 6 with respect to the ether group (position o and o′);
- B8 the phenylene ring Xis not substituted by —CH 3 , —C 2 H 5 , C 3 H 7 and/or C 4 H 9 .
- the preferred embodimemts cited above within the more preferred embodiment also comprise the combination of embodiment A with each of the embodiments B1, B2, B3, B4, B5, B6, B7 and B8.
- R 1 is a higher noncyclic or cyclic aliphatic group, starting from C 4 , i.e. if R 1 is a group selected from those which have been cited beforehand within the embodiments A.
- X is an aromatic cycle selected from a phenylene ring C 6 H 4 , in which one or more H atoms are optionally replaced independently by one or more of the substituents Z; or X is a 6-membered aromatic heterocycle containing 1 N atom, in which one or more H atoms are optionally replaced independently by one or more of the substituents Z;
- R 1 is selected from: H; linear and branched, unsubstituted and substituted C 1 -C 6 alkyl; linear and branched, unsubstituted and substituted C 2 -C 6 alkenyl; linear and branched, unsubstituted and substituted C 2 -C 6 alkynyl; substituted and unsubstituted C 3 -C 6 cycloalkyl; substituted and unsubstituted C 5 -C 6 cycloalkenyl; adamantyl and norbornyl; and wherein the named alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl and norbornyl groups can be substituted by F, (i.e. in case the named groups are substituted, the substituent is F), and wherein the named groups can be single or multiple substituted (i.e. in case the named groups are substituted, they carry one, two or more F);
- R 2 -R 5 are independently of each other selected from: H; F, Cl, Br, I; unsubstituted and substituted C 1 -C 2 alkyl, C 2 -alkenyl and C 2 -alkynyl, and wherein the substituents of the named alkyl, alkenyl and alkynyl groups can be F (i.e. in case the named groups are substituted, the substituent is F);
- Y is O or S
- Z is selected from F, Cl, Br, I; unsubstituted and substituted C 1 -C 2 alkyl, C 2 -alkenyl and C 2 -alkynyl, and wherein the substituents of the named alkyl, alkenyl and alkynyl groups can be F (i.e. in case the named groups are substituted, the substituent is F);
- R 6 is selected from: OR 7 , NR 8 R 9 , NHOH;
- R 7 is selected from H and linear and branched C 1 -C 4 alkyl
- R 8 and R 9 are independently of each other selected from H and linear and branched C 1 -C 4 alkyl.
- R 1 is selected from linear and branched, unsubstituted and substituted C 4 , C 5 and C 6 alkyl; linear and branched, substituted and unsubstituted C 4 , C 5 and C 6 alkenyl; linear and branched, unsubstituted and substituted C 4 , C 5 and C 6 alkynyl; substituted and unsubstituted C 4 , C 5 and C 6 cycloalkyl; substituted and unsubstituted C 5 and C 6 cycloalkenyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl and norbornyl groups are selected from the group F, Cl, Br, I, —CN, —NCO, —NCS, N 3 , and wherein the named groups can be single or multiple substituted (i.e. in case
- the phenylene ring X is not substituted, or monosubstituted (i.e. contains 0 or 1 substituent Z other than H);
- the phenylene ring X is not substituted by F, Cl, Br or I (substituent Z) in position 2 and 6 with respect to the ether group (position o and o′); and/or
- the phenylene ring X is not substituted by —CH 3 , —C 2 H 5 , C 3 H 7 and/or C 4 H 9 (substituent Z) in position 2 and 6 with respect to the ether group (position o and o′);
- B8 the phenylene ring Xis not substituted by —CH 3 , —C 2 H 5 , C 3 H 7 and/or C 4 H 9 .
- the preferred embodimemts cited above within the even more preferred embodiment also comprise the combination of embodiment A with each of the embodiments B1, B2, B3, B4, B5, B6, B7 and B8.
- R 1 is a higher noncyclic or cyclic aliphatic group, starting from C 4 , i.e. if R 1 is a group selected from those which have been cited beforehand within the embodiments A.
- X is an aromatic cycle selected from a phenylene ring C 6 H 4 , in which one or more H atoms are optionally replaced independently by one or more of the substituents Z; or X is a 6-membered aromatic heterocycle containing 1 N atom, in which one or more H atoms are optionally replaced independently by one or more of the substituents Z;
- R 1 is selected from: H; linear and branched, unsubstituted and substituted C 1 -C 6 alkyl; substituted and unsubstituted C 3 -C 6 cycloalkyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, cycloalkyl, adamantyl and norbornyl groups can be F (i.e. in case the named groups are substituted, the substituent is F), and wherein the named groups can be single or multiple substituted (i.e. in case the named groups are substituted, they carry one, two or several F);
- R 2 -R 5 are independently of each other selected from: H; F; unsubstituted and substituted C 1 -C 2 alkyl, and wherein the substituents of the named alkyl groups can be F (i.e. in case the named alkyl groups are substituted, the substituent is F);
- Y is O.
- Z is selected from F, Cl, Br, I; unsubstituted and substituted C 1 -C 2 alkyl, and wherein the named alkyl groups can be substituted by F (i.e. in case the named alkyl groups are substituted, the substituent is F);
- R 6 is selected from: OR 7 , NR 8 R 9 ;
- R 7 is selected from H and linear and branched C 1 -C 4 alkyl
- R 8 and R 9 are independently of each other selected from H and linear and branched C 1 -C 4 alkyl.
- R 1 is selected from: linear and branched, unsubstituted and substituted C 1 -C 6 alkyl; substituted and unsubstituted C 3 -C 6 cycloalkyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, cycloalkyl, adamantyl and norbornyl groups can be F (i.e. in case the named groups are substituted, the substituent is F), and wherein the named groups can be single or multiple substituted (i.e. in case the named groups are substituted, they carry one, two or several F).
- R 1 is selected from: H, linear and branched, unsubstituted and substituted C 4 , C 5 and C 6 alkyl; substituted and unsubstituted C 4 , C 5 and C 6 cycloalkyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, cycloalkyl, adamantyl and norbornyl groups can be F (i.e. in case the named groups are substituted, the substituent is F), and wherein the named groups can be single or multiple substituted, i.e.
- the named groups can carry one, two or several F (first preferred embodiment); or R 1 is selected from: linear and branched, unsubstituted and substituted C 4 , C 5 and C 6 alkyl; substituted and unsubstituted C 4 , C 5 and C 6 cycloalkyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, cycloalkyl, adamantyl and norbornyl groups can be F (i.e. in case the named groups are substituted, the substituent is F), and wherein the named groups can be single or multiple substituted (i.e. the named groups can carry one, two or several F) (second preferred embodiment).
- first preferred embodiment R 1 is selected from: linear and branched, unsubstituted and substituted C 4 , C 5 and C 6 alkyl; substituted and unsubstituted C 4 , C 5 and C 6 cycloalkyl; adamantyl and norbornyl
- the phenylene ring X is not substituted, or monosubstituted (i.e. contains 0 or 1 substituent Z other than H);
- the phenylene ring X is not substituted by F, Cl, Br or I (substituent Z) in position 2 and 6 with respect to the ether group (position o and o′); and/or
- the phenylene ring X is not substituted by —CH 3 , —C 2 H 5 , C 3 H 7 and/or C 4 H 9 (substituent Z) in position 2 and 6 with respect to the ether group (position o and o′);
- B8 the phenylene ring Xis not substituted by —CH 3 , —C 2 H 5 , C 3 H 7 and/or C 4 H 9 .
- the preferred embodimemts cited above within the first and second most preferred embodiment also comprise the combination of embodiment A with each of the embodiments B1, B2, B3, B4, B5, B6, B7 and B8.
- R 1 is a higher noncyclic or cyclic aliphatic group, starting from C 4 , i.e. if R 1 is a group selected from those which have been cited beforehand within the embodiments A.
- R 1 is selected from: H; linear and branched, unsubstituted and substituted C 1 -C 6 alkyl, preferably linear and branched, substituted an unsubstituted C 1 -C 5 alkyl; substituted and unsubstituted C 3 -C 6 cycloalkyl; adamantanyl and norbornyl; and wherein the named alkyl, cycloalkyl, adamantanyl and norbornyl groups can be substituted by F (i.e. in case the named groups are substituted, the substituent is F), and wherein the named groups can be single or multiple substituted (i.e.
- R 2 -R 5 , X, Y, Z, R 6 , R 7 , and R 8 and R 9 have the meanings as defined in the general, the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiments.
- R 6 , R 7 , and R 8 and R 9 have the meanings as defined in the general, the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiments.
- the following embodiments A are preferred in case X is a phenylene ring:
- R 1 is selected from: H, linear and branched, unsubstituted and substituted C 4 , C 5 and C 6 alkyl; substituted and unsubstituted C 4 , C 5 and C 6 cycloalkyl, preferably C 5 and C 6 cycloalkyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, cycloalkyl, adamantyl and norbornyl groups can be F (i.e. in case the named groups are substituted, the substituent is F), and wherein the named groups can be single or multiple substituted (i.e.
- R 2 -R 5 , X, Y, Z, R 6 , R 7 , and R 8 and R 9 have the meanings as defined in the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiments; wherein the substituents and substitution patterns for the phenylene ring X are as set forth in the embodiments B1, B2, B3, B4, B5, B6 and B7.
- the present preferred embodimemts cited above also comprise the combination of embodiment A with each of the embodiments B1, B2, B3, B4, B5, B6, B7 and B8.
- R 1 is a higher noncyclic or cyclic aliphatic group, starting from C 4 , i.e. if R 1 is a group selected from those which have been cited beforehand within the embodiments A.
- R 1 is selected from: linear and branched, unsubstituted and substituted C 1 -C 6 alkyl, preferably linear and branched, substituted an unsubstituted C 1 -C 6 alkyl; substituted and unsubstituted C 3 -C 6 cycloalkyl; adamantanyl and norbornyl; and wherein the named alkyl, cycloalkyl, adamantanyl and norbornyl groups can be substituted by F (i.e. in case the named groups are substituted, the substituent is F), and wherein the named groups can be single or multiple substituted (i.e.
- R 2 -R 5 , X, Y, Z, R 6 , R 7 , and R 8 and R 9 have the meanings as defined in the general, the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiments.
- R 6 , R 7 , and R 8 and R 9 have the meanings as defined in the general, the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiments.
- the following embodiments A are preferred in case X is a phenylene ring:
- R 1 is selected from: linear and branched, unsubstituted and substituted C 4 , C 5 and C 6 alkyl; substituted and unsubstituted C 4 , C 5 and C 6 cycloalkyl, preferably C 5 and C 6 cycloalkyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, cycloalkyl, adamantyl and norbornyl groups can be F (i.e. in case the named groups are substituted, the substituent is F), and wherein the named groups can be single or multiple substituted (i.e.
- R 2 -R 5 , X, Y, Z, R 6 , R 7 , and R 8 and R 9 have the meanings as defined in the general, the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiments; wherein the substituents and substitution patterns for the phenylene ring X are as set forth in the embodiments B1, B2, B3, B4, B5, B6 and B7.
- the present preferred embodimemts cited above also comprise the combination of embodiment A with each of the embodiments B1, B2, B3, B4, B5, B6, B7 and B8.
- R 1 is a higher noncyclic or cyclic aliphatic group, starting from C 4 , i.e. if R 1 is a group selected from those which have been cited beforehand within the embodiments A.
- R 1 is a group selected from —C(CH 3 ) 3 , —C(CH 3 ) 2 C 2 H 5 , cyclohexyl and adamantanyl, and R 2 -R 5 , X, Y, Z, R 6 , R 7 , and R 8 and R 9 have the meanings as defined in the general, the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiment, including the definitions for the case that X is a substituted or non substituted phenylene group.
- the carbonyl derived group —C(Y)R 6 connected to the aromatic ring is in position 4 with respect to the ether bridge, and R 1 , R 2 -R 5 , X, Y, Z, R 6 , R 7 , and R 8 and R 9 have the meanings as defined in the general, the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiment, including the definitions for the case that X is a substituted or non substituted phenylene group.
- X is an aromatic cycle selected from a phenylene ring C 6 H 4 , in which one or more H atoms are optionally replaced independently by one or more of the substituents Z; or X is a 6-membered aromatic heterocycle containing 1 N atom, in which one or more H atoms are optionally replaced independently by one or more of the substituents Z; and R 1 , R 2 -R 5 , X, Y, Z, R 6 , R 7 , and R 8 and R 9 have the meanings as defined in the general, the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiment, including the definitions for the case that X is a substituted or non substituted phenylene group.
- X is an aromatic cycle selected from a phenylene ring C 6 H 4 , in which one or more H atoms are optionally replaced independently by one or more of the substituents Z; or X is a 6-membered aromatic heterocycle containing 1 N atom in position 2 with respect to the ether bridge, in which one or more H atoms are optionally replaced independently by one or more of the substituents Z; and R 1 , R 2 -R 5 , X, Y, Z, R 6 , R 7 , and R 8 and R 9 have the meanings as defined in the general, the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiments, including the definitions for the case that X is a substituted or non substituted phenylene group.
- mammals as used in the context of the present application includes any kind of animals, preferably mammals, and even more preferred humans.
- Preferred compounds according to the present invention showing Notch signaling enhancing activities are depicted below.
- each compound may fall into the group of the general compounds of the invention as defined in connection with the general formula I, or into the group of preferred compounds, more preferred compounds, even more preferred compounds, first most preferred or second most preferred compounds as defined beforehand.
- the present invention also relates to a compound showing the general formula (I) and/or a pharmaceutically acceptable salt or ester thereof, in all preferred, more preferred, even more preferred, first most preferred and second most preferred embodiments, and of the individual compounds depicted above, for enhancing Notch signaling in an individual.
- the present invention also comprises a method of treating a disease in an individual, comprising administering a compound showing the general formula (I) and/or a pharmaceutically acceptable salt or ester thereof, in all general, preferred, more preferred, even more preferred, first most preferred and second most preferred embodiments, and of the individual compounds depicted above, to the individual.
- the diseases which can be treated with the compounds of the invention include diseases selected from the group of dermatological disorders including atopic dermatitis, psoriasis, immune related disorders, cancer including but not limited to squamous cell carcinoma, for example cutaneous and lung squamous cell carcinoma, head and neck cancer, non-melanoma skin cancer, basal cell carcinoma and actinic keratosis, neuroendocrine tumors, for example neuroendocrine small cell carcinoma and carcinoid tumors, thyroid carcinomas; and muscular disorders including muscular dystrophy and impaired regeneration capacity after injury; and the compounds of the invention can be used in immunotherapy for cancer.
- dermatological disorders including atopic dermatitis, psoriasis, immune related disorders
- cancer including but not limited to squamous cell carcinoma, for example cutaneous and lung squamous cell carcinoma, head and neck cancer, non-melanoma skin cancer, basal cell carcinoma and actinic keratosis, neuroendocrine tumors, for example neuroendoc
- the term “impaired regeneration after injury” preferably relates to muscle injury caused by: diseases such as muscle dystrophy; exposure to myotoxic agents, such as hypivacaine or lidocaine; sharp or blunt trauma, such as punctures or contusions; ischemia; exposure to hot or cold temperatures; the muscle's own contraction, for example in exercise-induced muscle damage and regeneration, in particular following eccentric exercise.
- Diseases which are preferably treated by the compounds of the invention include atopic dermatitis, psoriasis, squamous cell carcinoma, for example cutaneous and lung squamous cell carcinoma, non-melanoma skin cancer, head and neck cancer, basal cell carcinoma and actinic keratosis.
- Diseases which are most preferably treated by the compounds of the invention include immune related disorders.
- the compounds are used in immunotherapy for cancer.
- the diseases named above in the general, preferred and most preferred embodiments are caused by low Notch signaling and can thus be treated by administering the compounds according to the invention.
- the compounds of the invention are not used for treating prostate cancer (prostate carcinoma), in particular in case X is a phenylene ring.
- the invention relates to the compounds as defined in connection with formula (I)) and/or a pharmaceutically acceptable salt or ester thereof, including all preferred, more preferred, even more preferred, first most preferred and second most preferred embodiments, and of the individual compounds depicted above, for the treatment of a disease selected from the group of dermatological disorders including atopic dermatitis, psoriasis, immune related disorders, cancer including but not limited to squamous cell carcinoma, for example cutaneous and lung squamous cell carcinoma, head and neck cancer, non-melanoma skin cancer, basal cell carcinoma and actinic keratosis; neuroendocrine tumors, for example neuroendocrine small cell carcinoma and carcinoid tumors, and thyroid carcinomas, muscular disorders including muscular dystrophy and impaired regeneration capacity after injury, as well as for the use in immunotherapy for cancer.
- the invention does not relate to the cited compounds for the treatment of prostate cancer (prostate carcinoma), in particular in case X is a pheny
- Diseases which are preferably treated by the compounds of the invention include atopic dermatitis, psoriasis, squamous cell carcinoma, for example cutaneous and lung squamous cell carcinoma, non-melanoma skin cancer, head and neck cancer, basal cell carcinoma and actinic keratosis.
- Diseases which are most preferably treated by the compounds of the invention include immune related disorders.
- the compounds are used in immunotherapy for cancer.
- the present invention also relates to the compounds as defined in connection with formula (I) and/or a pharmaceutically acceptable salt or ester thereof, including all preferred, more preferred, even more preferred, first most preferred and second most preferred embodiments, and of the individual compounds depicted above, for use as a medicament, except for those compounds of which it is known that they can be used as a medicament (pharmaceutical activity) is known.
- the present invention also relates to the compounds as defined in connection with formula (I), including all preferred, more prefered, even more preferred, first most preferred and second most preferred embodiments as such. Compounds which are known as such are not an embodiment of the present invention.
- Still further compounds according to formula (I) known as such are the compounds of formula (Ia) wherein all of R 2 -R 5 are H, the phenylene ring is not substituted by Z, —C(Y)R 6 is in position 4 with respect to the ether bridge, Y is O, R 6 is OR 7 , R 7 is H, and R 1 is i-propyl or cyclohexyl; and compounds of formula (Ia) wherein all of R 2 -R 5 are H, the phenylene ring is substituted by CI (substituent Z) in position 2 with respect to the ether bridge, —C(Y)R 6 is in position 4 with respect to the ether bridge, Y is O, R 6 is OR 7 , R 7 is H, and R 1 is H, i-propyl or norbornyl; and the compound of formula (Ia) wherein all of R 2 -R 5 are H, the phenylene ring is substituted by F (substituent Z)
- the present invention also relates to the compounds as defined in connection with formula (I) and/or a pharmaceutically acceptable salt or ester thereof, including all general, preferred, more preferred, even more preferred, first most preferred and second most preferred embodiments, and of the individual compounds depicted above, for use as a medicament in combination therapy, wherein the said compounds are administered in combination with another method of treatment including but not limited to surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy.
- the present invention also comprises the use of these above defined compounds in combination therapy for the treatment of for the treatment of a disease selected from the group of dermatological disorders including atopic dermatitis, psoriasis, immune related disorders, cancer including but not limited to squamous cell carcinoma, for example cutaneous and lung squamous cell carcinoma, head and neck cancer, non-melanoma skin cancer, basal cell carcinoma and actinic keratosis; neuroendocrine tumors, for example neuroendocrine small cell carcinoma and carcinoid tumors, and thyroid carcinomas, muscular disorders including muscular dystrophy and impaired regeneration capacity after injury, as well as for the use in immunotherapy for cancer.
- the invention does not relate to the cited compounds for the treatment of prostate cancer (prostate carcinoma), in particular in case X is a phenylene ring.
- the compounds can be used for enhancing Notch signaling, as et forth below.
- the Notch receptor is synthesized as a 300 kDa precursor that is cleaved by furin-like convertase(s) in the trans-Golgi compartment.
- the resulting extracellular/lumenal N-terminal fragment and transmembrane domain/intracellular domain C-terminal fragment are assembled into the mature heterodimer receptor through a noncovalent linkage.
- the extracellular/lumenal portion of Notch undergoes extensive N- and O-linked glycosylation during Notch synthesis and secretion, which is critical for proper folding of the receptor and its subsequent interactions with ligands.
- Notch signal transduction is initiated by ligand binding and endocytosis, which generate the forces needed to expose an otherwise inaccessible ADAM10/TACE/Kuz/SUP-17 cleavage site in the extracellular portion of the Notch C-terminal fragment. Cleavage at this site produces the activated, membrane-anchored Notch form termed Notch extracellular truncation (NEXT). NEXT is subsequently cleaved by the intramembrane aspartyl protease complex y-secretase, leading to release of the Notch intracellular signal-transducing fragment termed Notch intracellular domain (NICD). This cleavage can occur at the cell surface and within the endosomal trafficking pathway.
- Notch extracellular truncation NEXT
- NEXT intramembrane aspartyl protease complex y-secretase
- Notch target genes are maintained in an actively repressed state through the formation of transcriptional complexes involving CSL transcription factors and various corepressors (CoRep).
- CoRep various corepressors
- corepressors associated with CSL are displaced and a transcriptionally active complex consisting of CSL, NICD, Mastermind (Mam), and coactivators (CoAct) assembles, leading to activation of Notch target genes.
- This schematic presents a simplified overview of the main conserved features of Notch synthesis and signaling; details of the biochemical mechanisms involved are omitted for the sake of clarity, the positions of the Notch diagrams are not intended to accurately depict the topology of Notch in various membrane compartments, and the glycosylation symbols and transcriptional complex diagrams are illustrative and do not imply specific glycosylation site locations or protein-protein interactions.
- a Notch signaling enhancing compound according to the invention leads to either a normalization of the level of the Notch target genes (as found in healthy individuals), or even to a level higher than that found in healthy individuals,
- the term “enhancing Notch signaling” refers to an effect on a cellular Notch-driven luciferase reporter assay, by which the Notch signaling enhancing properties of the compounds of the invention are determined.
- the Notch-driven luciferase reporter assay consists of HeLa cells engineered to express the Notch1 full length receptor, and to harbor a CSL-driven firefly luciferase expression construct as well as a Notch independent Renilla luciferase construct for the purpose of normalisation. These cells are co-cultured with engineered HeLa cells expressing the Notch ligand DII4 to induce Notch signaling, thus to induce the expression of the firefly luciferase enzyme.
- the intensity of a luciferase-driven reporter signal is considered as a measure for Notch signaling.
- a compound is considered as having an effect of enhancing Notch signaling if said compound results relative to DMSO in ⁇ 1.5-fold increase, preferably in ⁇ 2.0-fold increase, more preferably in ⁇ 2.5-fold increase and most preferably in ⁇ 3.0-fold increase of the Luciferase-driven reporter signal in the frame of the named Notch-dependent luciferase reporter assay.
- Notch was historically identified as an oncogene, studies within the last decade have also demonstrated the tumor suppressive effects of Notch signaling (Koch and Radtke, 2010) (South et al., 2012). In particular in tissues in which Notch signaling induces differentiation such as the skin, and neuroendocrine organs, Notch functions as a tumor suppressor.
- Notch signaling in cancers including but not limited to cutaneous and lung squamous cell carcinoma (Wang et al., 2011), head and neck cancer (Agrawal et al., 2011; Stransky et al., 2011), neuroendocrine tumors such as thyroid carcinoma (Yu et al., 2013), or neuroendocrine small cell carcinoma (Sriuranpong et al., 2001) and carcinoid tumors (Greenblatt et al., 2007) will induce differentiation and block growth of cancer cells.
- Compounds according to the invention which contain one or more acidic groups can be used according to the invention, e.g. as alkali metal salts, alkaline earth metal salts or as ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, e.g. ethylamine, ethanolamine, triethanolamine or amino acids.
- esters are those according to formula (I) in which H of the carboxy or the thiocarboxy group is replaced by an organic residue.
- Suitable organic residues are known to a person skilled in the art. Preferred organic residues include the following:
- An unsubstituted or at least monosubstituted alkyl preferably a C 1 -C 10 alkyl, an alkenyl, preferably C 2 -C 10 -alkenyl, an alkynyl, preferably C 3 -C 10 -alkynyl, and an unsubstituted or at least monosubstituted, saturated or unsaturated, non-aromatic or aromatic ring having 3 to 6 C-atoms, and which may contain in the ring one or more heteroatoms from the group N, S or O, and which heteroatom may be identical or different if more than one heteroatom is present.
- Said substituents being selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, N, S, O, carboxy, sulphonyl, and the like and which can be further substituted.
- Examples for current aromatic groups include aryl groups, for example phenyl groups, and heteroaryl groups, which aryl and heteroaryl groups may be substituted, preferably by the substituents given above.
- C 1 -C 4 -alkyl refers to methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl and tert.-butyl.
- C 3-7 cycloalkyl or “C 3-7 cycloalkyl ring” means a cyclic alkyl chain having 3-7 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl. Each hydrogen of a cycloalkyl carbon may be replaced by a substituent.
- Heterocyclyl or “heterocycle” means a cyclopentane, cyclohexane or cycloheptane ring that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated) wherein at least one carbon atom up to 4 carbon atoms are replaced by a heteroatom selected from the group consisting of sulfur (including —S(O)—, —S(O) 2 —), oxygen and nitrogen (including ⁇ N(O)—) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom.
- heterocycle examples include but are not restricted to furan, thiophene, pyrrole, pyrroline, imidazole, imidazoline, pyrazole, pyrazoline, oxazole, oxazoline, isoxazole, isoxazoline, thiazole, thiazoline, isothiazole, isothiazoline, thiadiazole, thiadiazoline, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, sulfolane, pyran, dihydropyran, tetrahydropyran, imidazolidine, pyridine, pyridazine, pyrazine, pyrimidine, piperazine, piperidine, morpholine, tetrazole, tri
- Suitable salts include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, napthalenedisulfonic acid, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfamic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid and other acids known to a person skilled in the art.
- pharmaceutically acceptable means approved by a regulatory agency such as the EMEA (Europe) and/or the FDA (US) and/or any other national regulatory agency for use in animals, preferably in humans.
- the invention also includes, in addition to the salt forms mentioned, inner salts or betaines.
- the respective salts of the compounds according to the invention can be obtained by customary methods which are known to the person skilled in the art, for example by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts.
- the invention includes all salts of the compounds according to the invention which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts or which might be suitable for studying Notch signaling activity of a compound according of the invention in any suitable manner, such as any suitable in vitro assay.
- the present invention furthermore includes all solvates and tautomers of the compounds according to the invention.
- the present invention furthermore includes derivatives/prodrugs (including the salts thereof) of the compounds according to the invention which contain physiologically tolerable and cleavable groups and which are metabolized in animals, preferably mammals, most preferably humans into a compound according to the invention.
- the present invention furthermore includes the metabolites of the compounds according to the invention.
- metabolites refers to all molecules derived from any of the compounds according to the invention in a cell or organism, preferably mammal.
- the term relates to molecules which differ from any molecule which is present in any such cell or organism under physiological conditions
- the compounds of the formula (I) can be purified by customary purification procedures, for example by recrystallization or chromatography.
- the starting compounds for the preparation of the compounds of the formula (I) are commercially available or can be prepared according to or analogously to literature procedures.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound as defined in connection with formula (I), including all preferred, more preferred, even more preferred, first most preferred and second most preferred embodiments, in admixture with an inert carrier, wherein said inert carrier is a pharmaceutical carrier.
- carrier refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered.
- Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, including but not limited to peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered orally.
- Saline and aqueous dextrose are preferred carriers when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions are preferably employed as liquid carriers for injectable solutions.
- Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
- the composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
- These compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations and the like.
- the composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides.
- Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by E. W. Martin. Such compositions will contain a therapeutically effective amount of the therapeutic, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.
- the invention relates to a method for the preparation of a compound according to the invention comprising the steps of coupling, preferably via S N Ar coupling, of substituted phenols with electron-poor aromatic (heteroaromatic) halides.
- the so-synthesized biaryl ethers are further derivatized by procedures including hydrolysis, esterification and amidation.
- Compounds can be purified by acid-base extraction, or by column chromatography on silica gel, or precipitation/recrystallization, or by other methods of purification known to a person skilled in the art including preparative thin layer chromatography (TLC) and high performance liquid chromatography (HPLC).
- the compounds according to the invention and their pharmaceutically acceptable salts, optionally in combination with other pharmaceutically active compounds suitable to enhance Notch signaling and/or to treat or prevent the above-cited disease or with any other of the drugs known to a person skilled in the art suitable to enhance Notch signaling and/or treat or prevent these diseases can be administered to animals, preferably to mammals, and in particular humans, as pharmaceuticals by themselves, in mixtures with one another or in the form of pharmaceutical preparations.
- Various delivery systems are known and can be used to administer a compound of the invention for enhancing Notch signaling and/or to treat the diseases cited, e.g. encapsulation in liposomes, microparticles, and microcapsules:
- Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes.
- the compounds may be administered by any convenient route, for example by infusion, by bolus injection, by absorption through epithelial or mucocutaneous linings and may be administered together with other biologically active agents.
- Administration can be systemic or local.
- Pulmonary administration can also be employed, e.g. by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.
- the therapeutic can be delivered in a vesicle, in particular a liposome (Langer (1990) Science 249:1527-1533; Treat et al. (1989) Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler, eds., Liss, New York, 353-365; Lopez-Berestein, ibid., 317-327)
- the therapeutic can be delivered via a controlled release system.
- a pump may be used (Sefton (1987) CRC Crit. Ref. Biomed. Eng. 14:201-240; Buchwald et al. (1980) Surgery 88:507-516; Saudek et al. (1989) N. Engl. J. Med. 321:574-579).
- polymeric materials can be used (Medical Applications of Controlled Release, Langer and Wise, eds., CRC Press, Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball, eds., Wiley, New York (1984); Ranger and Peppas (1983) Macromol. Sci. Rev. Macromol. Chem. 23:61; Levy et al. (1985) Science 228:190-192; During et al. (1989) Ann. Neurol. 25:351-356; Howard et al. (1989) J. Neurosurg. 71:858-863).
- a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (e.g. Goodson, 1984, In: Medical Applications of Controlled Release, supra, Vol. 2,115-138). Other controlled release systems are discussed in the review by Langer (1990, Science 249:1527 - 1533).
- drugs are being taken orally, has been launched both as tablets/liquid and as an i.v.-solution.
- suitable dosage ranges for intravenous administration are generally about 20-500 micrograms of active compound per kilogram body weight.
- suitable dosage ranges for intranasal administration are generally about 0.01 mg/kg body weight to 1 mg/kg body weight.
- Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
- the reaction was quenched by addition of water, extracted with organic solvent (preferably Et 2 O, EtOAc and DCM depending on the substrate).
- organic solvent preferably Et 2 O, EtOAc and DCM depending on the substrate.
- the combined organic layers were washed with sat. aqueous NaCl solution, dried over Na 2 SO 4 and evaporated to dryness under reduced pressure.
- the crude product was purified by flash column chromatography to give the desired biarylether.
- R 6 is an alkoxy group, preferably OC 2 H 5
- ester A solution of the respective ester, preferably the ethyl ester in EtOH/0.5 M NaOH was stirred at a temperature between 40° C. and 120° C. depending on the substrate, preferably 80° C. until the complete consumption of the starting materials.
- the reaction mixture was cooled down to room temperature and then concentrated under reduced pressure.
- the residue was dissolved in water, acidified, and extracted with an appropriate organic solvent (preferably EtOAC or DCM).
- EtOAC or DCM an appropriate organic solvent
- the combined organic layers were washed with sat. aqueous NaCl solution, dried over Na 2 SO 4 and evaporated to dryness under reduced pressure.
- the crude product was purified by column chromatography on silica gel, or by recrystallization to give the desired carboxylic acid.
- R 6 is an alkoxy group, preferably OC 2 H 5
- ester To a sealed tube were added a solution of the respective ester, preferably the ethyl ester and preferably calcium chloride in an appropriate solvent, preferably MeOH and a solution of NH 3 in an appropriate solvent, preferably MeOH. The mixture was stirred at a temperature between 40° C. and 120° C. depending on the substrate, preferably 80° C. until the reaction was completed. The reaction mixture was cooled down to room temperature and concentrated under reduced pressure. The residue was resolved in EtOAc and sat. aqueous NH 4 Cl solution. The aqueous phase was extracted with EtOAc. The combined organic layers were washed with sat. aqueous NaCl solution, dried over Na 2 SO 4 and evaporated to dryness under reduced pressure. The crude product was purified by flash column chromatography to give the desired amide.
- an appropriate solvent preferably MeOH and a solution of NH 3 in an appropriate solvent, preferably MeOH.
- FIG. 1 The respective Notch signaling-enhancing activities of the preferred molecules depicted above in a Notchl-driven luciferase assay are illustrated in FIG. 1 .
- a brief description of this Notch reporter assay is given in the caption of FIG. 1 .
- Derivative V126 was tested as representative compound in further experiments.
- FIG. 2 shows investigations using V126 in different settings within the luciferase reporter assay.
- V126 strongly enhanced Notch signaling already at a concentration of 1 ⁇ M, whereas the reported Notch enhancer valproic acid did not show any effect within the frame of the screened concentrations of up to 40 ⁇ M ( FIG. 2 a ).
- the Notch reporter assay was challenged by applying V126 treatment immediately prior to the readout. Short-term treatment yielded values in the range of the DMSO control level, whereas the corresponding treatment with V126 for 20 h in the very same readout resulted in the expected upregulation of the luciferase values ( FIG. 2 b ).
- V126 is able not only to enhance signaling derived from different Notch receptor isoforms, but also to enhance the signaling cascade taking place downstream of ligand-mediated activation of Notch signaling ( FIG. 2 d and e).
- Notch activation in the skin is known to drive differentiation of keratinocytes resulting in the induction of differentiation markers such as involucrin (C. Nowell, Cold Spring Harb Perspect Med. 2013, 3, 12,), (G. P. Dotto, Oncogene 2008, 27, 5115-5123). Therefore, V126 was further investigated by treatment of the human squamous cell carcinoma cell line SCC13 at a concentration of 10 ⁇ M. Increased expression of involucrin at the protein level was detected upon incubation with V126 for 48 h ( FIG. 3 ), suggesting that V126 is promoting differentiation in this cancer cell line via upregulation of Notch signaling.
- differentiation markers such as involucrin (C. Nowell, Cold Spring Harb Perspect Med. 2013, 3, 12,), (G. P. Dotto, Oncogene 2008, 27, 5115-5123). Therefore, V126 was further investigated by treatment of the human squamous cell carcinoma cell line SCC13 at a concentration of 10 ⁇ M. Increased expression of involucrin at the protein level was
- MZBs marginal zone B-cells
- FoBs follicular B-cells
- TBs transitional B-cells
- Notch2 signaling was reported to play a crucial role in the development of MZBs (S. Pillai, Nat. Rev. Immunol. 2009, 9, 767-777) and increased Notch2 signaling in the spleen leads to an expansion of the MZB compartment (F. Hampel, Blood 2011, 118, 24, 6321-6331).
- FoBs is not dependent on Notch signaling.
- V126 was capable to double the number of MZBs as compared to the control, whereas the FoB numbers were not affected ( FIG. 4 ).
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
- This application is a divisional of U.S. Ser. No. 16/085,372, filed Sep. 14, 2018, which is a 35 U.S.C. 371 National Phase Entry Application from PCT/EP2017/056461, filed Mar. 17, 2017, which claims the benefit of European Patent Application No. 16160988.8 filed on Mar. 17, 2016, the disclosures of which are incorporated herein in their entirety by reference.
- The present invention relates to compounds which are enhancers of Notch signaling and lend themselves for the treatment of Notch-associated malignancies, such as cancer, degenerative muscle diseases, skin diseases like psoriasis and atopic dermatitis, and immunological disorders, as well as for the use in immunotherapy for cancer.
- Notch signaling represents a short-range intercellular signaling pathway that plays a critical role during embryogenesis and adult tissue homeostasis. Depending on the cellular context, Notch signaling is involved in the regulation of cell fate determination, differentiation, apoptosis and proliferation, but also in stem cell maintenance. Presence and intensity of Notch signaling in the cellular frame are temporally and spatially strictly controlled. In consequence, abnormal Notch activity can lead to various disease situations. Although Notch was historically identified as an oncogene. studies within the last decade have also demonstrated the tumor suppressive effects of Notch signaling (Koch and Radtke, 2010) (South et al., 2012). In particular in tissues in which Notch signaling induces differentiation such as the skin, and neuroendocrine organs, Notch functions as a tumor suppressor. Thus activating or increasing Notch signaling in cancers including but not limited to cutaneous and lung squamous cell carcinoma (Wang et al., 2011), head and neck cancer (Agrawal et al., 2011; Stransky et al., 2011), neuroendocrine tumors such as thyroid carcinoma (Yu et al., 2013), or neuroendocrine small cell carcinoma (Sriuranpong et al., 2001) and carcinoid tumors (Greenblatt et al., 2007) will induce differentiation and block growth of cancer cells.
- Therefore, the development of tools to control Notch signaling is highly desirable.
- The present invention comprises for use a family of small molecules capable to enhance Notch signaling, resulting in the potential applications, which will be disclosed in the application. The applications are implementable in both human and veterinary medicine.
- STATE OF THE ART
- WO2013/093885 discloses 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine and derivatives thereof having Notch signalling pathway inhibition properties for the treatment and/or prevention of cancer, wherein the cancer is a Notch dependent cancer, and wherein the Notch dependent cancer is preferably selected from the group comprising T cell-Acute lymphoblastic leukemia (T-ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), breast cancer, pancreatic cancer, prostate cancer, melanoma, brain tumors, tumor angiogenesis, and colorectal cancer.
- Only a limited number of small molecules are reported in the literature that feature to activate Notch signaling, which comprise valproic acid (D. Y. Greenblatt, The Oncologist 2007, 12, 942-951; Mohammed et al., The Oncologist, 2011, 16, 835-843), resveratrol (S. N. Pinchot, Cancer 2011,117, 7, 1386-1398), phenethyl isothiocyanate (S.-H. Kim, PLoS One 2011, 6, 10) and some flavonoids, such as chrysin (X. M. Yu, Cancer 2013, 119, 4) or hesperetin (P. N. Patel, Ann Surg Oncol 2014). However, some of these molecules showed Notch enhancing properties only at high concentrations. Most of the listed compounds are already in clinical trials being investigated as anticancer drugs for a few different tumor types.
- Another approach to upregulate Notch signaling comprises the use of activating Notch ligand-mimicking peptides as for instance a JAG-1 protein peptide fragment (B. J. Nickoloff, Cell Death and Differentiation 2002, 9, 842-855). Nonetheless, this tool to trigger Notch signaling is still in development and only available for research yet.
- There is a need for potent Notch signaling enhancers that can be used to treat and prevent Notch-associated diseases, preferably dermatologic diseases, immunological disorders, muscular diseases e.g. muscular dystrophy and impaired regeneration capacity after injury, and cancer, e.g. squamous cell carcinoma, neuroendocrine tumors, thyroid carcinomas and others, as well as for immunotherapy against cancer.
- The following patent applications and scientific publications may be of interest in the context of the present application:
- WO 98/42328, PCT/US98/06037:
- “Di-aryl ethers and their derivatives as anti-cancer agents”.
- WO 93/24442, PCT/JP93/00710:
- “Medicine containing benzoic acid derivative as testosterone 5-reductase inhibitor and novel benzoic acid derivative”. This application discloses several benzoic acid derivatives which lend themselves as testosterone 5-reductase inhibitors and can, inter alia, be used for the treatment of prostate cancer (prostate carcinoma).
- WO 94/05153, PCT/US93/08096:
- “Herbicidal benzene compounds”.
- U.S. Pat. No. 5,438,033, PCT/US92/04644, WO92/22203:
- “Substituted pyridine herbicides”.
- Further patent applications and patents disclosing specific molecular structures are listed in the section Structures tested in the Notch reporter assay.
- Chemical and Pharmaceutical Bulletin 1999, 47, 8, 1073-1080, S. Igarashi et al: “A novel class of inhibitors for human steroid 5-reductase: phenoxybenzoic acid derivatives. I”.
- Bioorganic and Medicinal Chemistry Letters 2011, 21, 4215-4219, C. De Savi et al.: “Selective non zinc binding inhibitors of MMP13”.
- Bioorganic and Medicinal Chemistry Letters 2012, 22, 1788-1792, T. Nakamura et al.: “Discovery of CS-2100, a potent, orally active and S1P3-sparing SIP, agonist”.
- However, all compounds known hitherto which are used as Notch signaling enhancers and treating the diseases related thereto, have the above cited drawbacks
- Accordingly, one object underlying the present invention is to provide compounds acting as Notch signaling enhancers and which can be used to treat cancers and other diseases which cannot be treated by Notch signaling inhibitors, or provide compounds which render possible an alternative treatment to Notch signaling inhibitors, of the respective diseases. The diseases and cancers are in particular the cancers cited in WO 2013/093885.
- A further object underlying the present invention is to provide compounds acting as Notch signaling enhancers, are possible to treat the above-cited diseases and which preferably do not show the drawbacks of the known compounds.
- The present invention relates to the use for enhancing Notch signaling in an individual, of a compound showing the general formula (I)
- wherein
- X is an aromatic cycle selected from a phenylene ring C6H4, in which one or more H atoms are optionally replaced independently by one or more of the substituents Z; or X is a 6-membered aromatic heterocycle containing 1 or 2 N atoms, in which one or more H atoms are optionally replaced independently by one or more of the substituents Z;
- R1 is selected from: H; linear and branched, unsubstituted and substituted C1-C16 alkyl; linear and branched, unsubstituted and substituted C2-C8 alkenyl; linear and branched, unsubstituted and substituted C2-C8 alkynyl; substituted and unsubstituted C3-C8 cycloalkyl; substituted and unsubstituted C5-C8 cycloalkenyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl and norbornyl groups are selected from the group F, Cl, Br, I, —CN, —NCO, —NCS, N3, and wherein the named groups can be single or multiple substituted;
- R2-R5 are independently of each other selected from: H, F, Cl, Br, I; linear and branched, unsubstituted and substituted C1-C4 alkyl, C2-C4 alkenyl and C2-C4 alkynyl, cyclopropyl and cyclobutyl, and wherein the substituents of the named alkyl, alkenyl, alkynyl, cyclopropyl and cyclobutyl groups are selected from F, Cl, Br and I;
- Y is O or S;
- Z is selected from: F, Cl, Br, I, linear and branched, unsubstituted and substituted C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, cyclopropyl and cyclobutyl, and wherein the substituents of the named alkyl, alkenyl, alkynyl, cyclopropyl and cyclobutyl groups can be selected from F, Cl, Br and I;
- R6 is selected from: OR7, NR8R9, NHOH;
- R7 is selected from H and linear and branched C1-C6 alkyl;
- R8 and R9 are independently of each other selected from H and linear and branched C1-C6 alkyl;
- and/or a pharmaceutically acceptable salt or ester thereof.
- The term “substituted” as used herein includes both part and full substitution.
- Within the above defined most general embodiment of the invention, the following embodiments A are preferred in case X is a phenylene ring:
- R1 is selected from linear and branched, unsubstituted and substituted C4-C16 alkyl; linear and branched, substituted and unsubstituted C4-C8 alkenyl; linear and branched, unsubstituted and substituted C4-C8 alkynyl; substituted and unsubstituted C4-C8 cycloalkyl; substituted and unsubstituted C5-C8 cycloalkenyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl and norbornyl groups are selected from the group F, Cl, Br, I, —CN, —NCO, —NCS, N3, and wherein the named groups can be single or multiple substituted;
- In further embodiments within the above defined most general embodiment, the following embodiments B are preferred in case X is a phenylene ring as depicted in formula Ia:
- B1: the phenylene ring X is not substituted, or monosubstituted (i.e. contains 0 or 1 substituent Z other than H); and/or
- B2: the phenylene ring X is not substituted by I (substituent Z) in
position - B3: the phenylene ring X is not substituted by Br (substituent Z) in
position - B4: the phenylene ring X is not substituted by F, Cl, Br or I (substituent Z) in
position - B5: the phenylene ring X is not substituted by I (substituent Z); and/or
- B6: the phenylene ring X is not substituted by F, Cl, Br or I (substituent Z); and/or
- B6: the phenylene ring X is not substituted by —CH3 (substituent Z) in
position - B7: the phenylene ring X is not substituted by —CH3, —C2H5, C3H7 and/or C4H9 (substituent Z) in
position - B8: the phenylene ring X is not substituted by —CH3, —C2H5, C3H7 and/or C4H9.
- The preferred embodiments cited above within the most general embodiment also comprise the combination of embodiment A with each of the embodiments B1, B2, B3, B4, B5, B6, B7 and B8.
- It has proved advantageous in case X is a phenylene ring, if R1 is a higher noncyclic or cyclic aliphatic group, starting from C4, i.e. if R1 is a group selected from those which have been cited beforehand within the embodiments A.
- The term “alkyl” refers to an aliphatic saturated hydrocarbon group, including methyl (C1 alkyl), ethyl (C2 alkyl), n-propyl, iso-propyl (C3 alkyl), n-butyl, iso-butyl, sec.-butyl and tert.-butyl (C4 alkyl), n-pentyl (amyl), 2-pentyl (sec-pentyl), 3-pentyl; 2-methylbutyl, 3-methylbutyl (iso-pentyl or iso-amyl), 3-methylbut-2-yl, 2-methylbut-2-yl; 2,2-dimethylpropyl (neopentyl) (C5 alkyl), a hexyl group (C5 alkyl) including all isomers, a heptyl group (C7 alkyl) including all isomers, an octyl group (C8 alkyl) including all isomers, a nonyl group including all isomers (C9 alkyl), a decyl group including all isomers (C10 alkyl), an undecyl group including all isomers (C11 alkyl), a dodecyl group including all isomers (C12 alkyl), a tridecyl group including all isomers (C13 alkyl), a tetradecyl group group including all isomers (C14 alkyl), a pentadecyl group including all isomers (C15 alkyl), and a hexadecyl group including all isomers (C16 alkyl), as known to the person skilled in the art.
- The term “alkenyl” refers to an aliphatic unsaturated hydrocarbon group, including ethenyl (C2 alkenyl), n-propenyl, iso-propenyl (C3 alkenyl), n-butenyl, iso-butenyl, sec.-butenyl and tert.-butenyl (C4 alkenyl), a pentenyl group including all isomers (C5 alkenyl), a hexenyl group (C6 alkenyl) including all isomers, a heptenyl group including all isomers (C, alkenyl), an octenyl group including all isomers (C8 alkenyl), as known to the person skilled in the art.
- The term “alkynyl” refers to the above cited C2-C8 groups having a double bond, but having a triple bond and which are known to the person skilled in the art. Examples include ethynyl (C2 alkynyl), n-propynyl and iso-propynyl (C3 alkynyl), the various isomers of butynyl (C4 alkynyl), the various isomers of pentynyl (C5 alkynyl), the various isomers of hexynyl (C6 alkynyl), the various isomers of heptynyl (C7 alkynyl), and the various isomers of octynyl (C8 alkynyl).
- “Cycloalkyl” or “cycloalkyl ring” means an aliphatic cyclic saturated alkyl group, e.g. cyclopropyl (C3 cycloalkyl), cyclobutyl (C4 cycloalkyl), cyclopentyl (C5 cycloalkyl), cyclohexyl (C6 cycloalkyl), cycloheptyl (C7 cycloalkyl), cyclooctyl (C8 cycloalkyl). Each hydrogen of a cycloalkyl carbon may be replaced by a substituent.
- “Cycloalkenyl” or “cycloalkenyl ring” means a cyclic unsaturated (one or more double carbon-carbon bonds) aliphatic or aromatic group, e.g. cyclopropenyl (C3 cycloalkenyl), cyclobutenyl (C4 cycloalkenyl), cyclopentenyl (C5 cycloalkenyl), cyclohexenyl (C6 cycloalkenyl), cycloheptenyl (C7 cycloalkenyl), cyclooctenyl (C8 cycloalkenyl). Each hydrogen of a cycloalkyl carbon may be replaced by a substituent.
- The substituents R2, R3, R4 and R5 in case these are not H can be in the
positions - The carbonyl derived group —C(Y)R6 connected to the aromatic ring can be in
position - The substituent Z can be in the
positions - The term “6-membered aromatic heterocycle containing 1 or 2 N atoms” refers to a heterocycle containing either 1 N atom or 2 N atoms. This heterocycle is selected from pyridine, pyridazine, pyrimidine and pyrazine. In the compounds according to formula (I), the aromatic heterocycle is connected to O in the ether bridge via a chemical bond, and to the carbonyl derived group in another position of the heterocycle, meaning that at least two H atoms in the aromatic heterocycle are replaced by a chemical bond. Further H atoms, for example 1, 2, 3 or 4, preferably 1 H atom, may be replaced by the group Z.
- In an embodiment of the invention, the Notch signaling enhancing compound belongs to the family of phenoxybenzoic acids and phenoxynicotinic acids and derivatives thereof. The person skilled in the art is aware of appropriate derivates. Known examples include esters and amides.
- In a further embodiment of the invention, the invention relates to the compounds as defined in connection with formula (I) and/or a pharmaceutically acceptable salt or ester thereof, including all preferred, more preferred, even more preferred, first most preferred and second most preferred embodiments for the treatment of a disease associated with reduced Notch signaling activity.
- In a preferred embodiment of the present invention, the symbols R1 to R9, X, Y and Z have the following meanings:
- X is an aromatic cycle selected from a phenylene ring C6H4, in which one or more H atoms are optionally replaced independently by one or more of the substituents Z; or X is a 6-membered aromatic heterocycle containing 1 or 2 N atoms, in which one or more H atoms are optionally replaced independently by one or more of the substituents Z;
- R1 is selected from: H; linear and branched, unsubstituted and substituted C1-C12 alkyl; linear and branched, unsubstituted and substituted C2-C8 alkenyl; linear and branched, unsubstituted and substituted C2-C8 alkynyl; substituted and unsubstituted C3-C8 cycloalkyl; substituted and unsubstituted C5-C8 cycloalkenyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl and norbornyl groups are selected from the group F, Cl, Br, I, —CN, —NCO, —NCS, N3, and wherein the named groups can be single or multiple substituted (i.e. in case the named groups are substituted, they carry one, two or several of the named substituents);
- R2-R5 are independently of each other selected from: H, F, Cl, Br, I; unsubstituted and substituted C1-C2 alkyl, C2-alkenyl, C2-alkynyl, and wherein the named alkyl, alkenyl, and alkynyl groups can be substituted by F (i.e. in case the named groups are substituted, the substituent is F).
- Y is O or S;
- Z is selected from F, Cl, Br, I; unsubstituted and substituted C1-C2 alkyl, C2-alkenyl, C2-alkynyl, and wherein the substituent of the named alkyl, alkenyl and alkynyl groups can be F (i.e. in case the named groups are substituted, the substituent is F);
- R6 is selected from: OR7, NR8R9, NHOH;
- R7 is selected from H and linear and branched C1-C4 alkyl;
- and wherein at least one of R1, R2-R5 and Z is a substituent other than H,
- R8 and R9 are independently of each other selected from H and linear and branched C1-C4 alkyl.
- Within the above defined preferred embodiment of the invention, the following embodiments A are preferred in case X is a phenylene ring:
- R1 is selected from linear and branched, unsubstituted and substituted C4-C12 alkyl; linear and branched, substituted and unsubstituted C4-C8 alkenyl; linear and branched, unsubstituted and substituted C4-C8 alkynyl; substituted and unsubstituted C4-C8 cycloalkyl; substituted and unsubstituted C5-C8 cycloalkenyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl and norbornyl groups are selected from the group F, Cl, Br, I, —CN, —NCO, —NCS, N3, and wherein the named groups can be single or multiple substituted;
- In further embodiments within the above defined preferred embodiment, the following embodiments B are preferred in case X is a phenylene ring:
- B1: the phenylene ring X is not substituted, or monosubstituted (i.e. contains 0 or 1 substituent Z other than H); and/or
- B2: the phenylene ring X is not substituted by I (substituent Z) in
position - B3: the phenylene ring X is not substituted by Br (substituent Z) in
position - B4: the phenylene ring X is not substituted by F, Cl, Br or I (substituent Z) in
position - B5: the phenylene ring X is not substituted by I (substituent Z); and/or
- B6: the phenylene ring X is not substituted by F, Cl, Br or I (substituent Z); and/or
- B6: the phenylene ring X is not substituted by —CH3 (substituent Z) in
position - B7: the phenylene ring X is not substituted by —CH3, —C2H5, C3H7 and/or C4H9 (substituent Z) in
position - B8: the phenylene ring Xis not substituted by —CH3, —C2H5, C3H7 and/or C4H9.
- The preferred embodimemts cited above within the above defined preferred embodiment also comprise the combination of embodiment A with each of the embodiments B1, B2, B3, B4, B5, B6, B7 and B8.
- It has proved advantageous in case X is a phenylene ring, if R1 is a higher noncyclic or cyclic aliphatic group, starting from C4, i.e. if R1 is a group selected from those which have been cited beforehand within the embodiments A.
- In a more preferred embodiment of the present invention, the symbols R1 to R9, X, Y and Z have the following meanings:
- X is an aromatic cycle selected from a phenylene ring C6H4 , in which one or more H atoms are optionally replaced independently by one or more of the substituents Z; or X is a 6-membered aromatic heterocycle containing 1 or 2 N atoms, in which one or more H atoms are optionally replaced independently by one or more of the substituents Z;
- R1 is selected from: H; linear and branched, unsubstituted and substituted C1-C8 alkyl; linear and branched, unsubstituted and substituted C2-C6 alkenyl; linear and branched, unsubstituted and substituted C2-C6 alkynyl; substituted and unsubstituted C3-C6 cycloalkyl; substituted and unsubstituted C5-C6 cycloalkenyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl and norbornyl groups are selected from the group F, Cl, Br, I, —CN, —NCO, —NCS, N3, and wherein the named groups can be single or multiple substituted (i.e. in case the named groups are substituted, they carry one, two or several of the named substituents);
- R2-R6 are independently of each other selected from: H, F, Cl, Br, I; unsubstituted and substituted C1-C2 alkyl, C2-alkenyl, and C2-alkynyl, and wherein the substituents of the named alkyl, alkenyl and alkynyl groups can be F (i.e. in case the named groups are substituted, the substituent is F);
- Y is O or S;
- Z is selected from F, Cl, Br, I; unsubstituted and substituted C1-C2 alkyl C2-alkenyl, and C2-alkynyl, and wherein the substituents of the named alkyl, alkenyl and alkynyl groups can be F (i.e. in case the named groups are substituted, the substituent is F);
- R6 is selected from: OR7, NR8R9, NHOH;
- R7 is selected from H and linear and branched C1-C4 alkyl;
- R8 and R9 are independently of each other selected from H and linear and branched C1-C4 alkyl.
- Within the above defined more preferred embodiment of the invention, the following embodiments A are preferred in case X is a phenylene ring:
- R1 is selected from linear and branched, unsubstituted and substituted C4-C8 alkyl; linear and branched, substituted and unsubstituted C4-C6 alkenyl; linear and branched, unsubstituted and substituted C4-C6 alkynyl; substituted and unsubstituted C4-C6 cycloalkyl; substituted and unsubstituted C5-C6 cycloalkenyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl and norbornyl groups are selected from the group F, Cl, Br, I, —CN, —NCO, —NCS, N3, and wherein the named groups can be single or multiple substituted (i.e. in case the named groups are substituted, they carry one, two or several of the named substituents);
- In further embodiments within the above defined more preferred embodiment, the following embodiments B are preferred in case X is a phenylene ring:
- B1: the phenylene ring X is not substituted, or monosubstituted (i.e. contains 0 or 1 substituent Z other than H); and/or
- B2: the phenylene ring X is not substituted by I (substituent Z) in
position - B3: the phenylene ring X is not substituted by Br (substituent Z) in
position - B4: the phenylene ring X is not substituted by F, Cl, Br or I (substituent Z) in
position - B5: the phenylene ring X is not substituted by I (substituent Z); and/or
- B6: the phenylene ring X is not substituted by F, Cl, Br or I (substituent Z); and/or
- B6: the phenylene ring X is not substituted by —CH3 (substituent Z) in
position - B7: the phenylene ring X is not substituted by —CH3, —C2H5, C3H7 and/or C4H9 (substituent Z) in
position - B8: the phenylene ring Xis not substituted by —CH3, —C2H5, C3H7 and/or C4H9.
- The preferred embodimemts cited above within the more preferred embodiment also comprise the combination of embodiment A with each of the embodiments B1, B2, B3, B4, B5, B6, B7 and B8.
- It has proved advantageous in case X is a phenylene ring, if R1 is a higher noncyclic or cyclic aliphatic group, starting from C4, i.e. if R1 is a group selected from those which have been cited beforehand within the embodiments A.
- In an even more preferred embodiment of the present invention, the symbols R1 to R9, X, Y and Z have the following meanings:
- X is an aromatic cycle selected from a phenylene ring C6H4 , in which one or more H atoms are optionally replaced independently by one or more of the substituents Z; or X is a 6-membered aromatic heterocycle containing 1 N atom, in which one or more H atoms are optionally replaced independently by one or more of the substituents Z;
- R1 is selected from: H; linear and branched, unsubstituted and substituted C1-C6 alkyl; linear and branched, unsubstituted and substituted C2-C6 alkenyl; linear and branched, unsubstituted and substituted C2-C6 alkynyl; substituted and unsubstituted C3-C6 cycloalkyl; substituted and unsubstituted C5-C6 cycloalkenyl; adamantyl and norbornyl; and wherein the named alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl and norbornyl groups can be substituted by F, (i.e. in case the named groups are substituted, the substituent is F), and wherein the named groups can be single or multiple substituted (i.e. in case the named groups are substituted, they carry one, two or more F);
- R2-R5 are independently of each other selected from: H; F, Cl, Br, I; unsubstituted and substituted C1-C2 alkyl, C2-alkenyl and C2-alkynyl, and wherein the substituents of the named alkyl, alkenyl and alkynyl groups can be F (i.e. in case the named groups are substituted, the substituent is F);
- Y is O or S;
- Z is selected from F, Cl, Br, I; unsubstituted and substituted C1-C2 alkyl, C2-alkenyl and C2-alkynyl, and wherein the substituents of the named alkyl, alkenyl and alkynyl groups can be F (i.e. in case the named groups are substituted, the substituent is F);
- R6 is selected from: OR7, NR8R9, NHOH;
- R7 is selected from H and linear and branched C1-C4 alkyl;
- R8 and R9 are independently of each other selected from H and linear and branched C1-C4 alkyl.
- Within the above even more preferred embodiment of the invention, the following embodiments A are preferred in case X is a phenylene ring:
- R1 is selected from linear and branched, unsubstituted and substituted C4, C5 and C6 alkyl; linear and branched, substituted and unsubstituted C4, C5 and C6 alkenyl; linear and branched, unsubstituted and substituted C4, C5 and C6 alkynyl; substituted and unsubstituted C4, C5and C6 cycloalkyl; substituted and unsubstituted C5 and C6 cycloalkenyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl and norbornyl groups are selected from the group F, Cl, Br, I, —CN, —NCO, —NCS, N3, and wherein the named groups can be single or multiple substituted (i.e. in case the named groups are substituted, they carry one, two or several of the named substituents);
- In further embodiments within the above defined even more preferred embodiment, the following embodiments B are preferred in case X is a phenylene ring:
- B1: the phenylene ring X is not substituted, or monosubstituted (i.e. contains 0 or 1 substituent Z other than H); and/or
- B2: the phenylene ring X is not substituted by I (substituent Z) in
position - B3: the phenylene ring X is not substituted by Br (substituent Z) in
position - B4: the phenylene ring X is not substituted by F, Cl, Br or I (substituent Z) in
position - B5: the phenylene ring X is not substituted by I (substituent Z); and/or
- B6: the phenylene ring X is not substituted by F, Cl, Br or I (substituent Z); and/or
- B6: the phenylene ring X is not substituted by —CH3 (substituent Z) in
position - B7: the phenylene ring X is not substituted by —CH3, —C2H5, C3H7 and/or C4H9 (substituent Z) in
position - B8: the phenylene ring Xis not substituted by —CH3, —C2H5, C3H7 and/or C4H9.
- The preferred embodimemts cited above within the even more preferred embodiment also comprise the combination of embodiment A with each of the embodiments B1, B2, B3, B4, B5, B6, B7 and B8.
- It has proved advantageous in case X is a phenylene ring, if R1 is a higher noncyclic or cyclic aliphatic group, starting from C4, i.e. if R1 is a group selected from those which have been cited beforehand within the embodiments A.
- In the first most preferred embodiment of the present invention, the symbols R1 to R9, X, Y and Z have the following meanings:
- X is an aromatic cycle selected from a phenylene ring C6H4, in which one or more H atoms are optionally replaced independently by one or more of the substituents Z; or X is a 6-membered aromatic heterocycle containing 1 N atom, in which one or more H atoms are optionally replaced independently by one or more of the substituents Z;
- R1 is selected from: H; linear and branched, unsubstituted and substituted C1-C6 alkyl; substituted and unsubstituted C3-C6 cycloalkyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, cycloalkyl, adamantyl and norbornyl groups can be F (i.e. in case the named groups are substituted, the substituent is F), and wherein the named groups can be single or multiple substituted (i.e. in case the named groups are substituted, they carry one, two or several F);
- R2-R5 are independently of each other selected from: H; F; unsubstituted and substituted C1-C2 alkyl, and wherein the substituents of the named alkyl groups can be F (i.e. in case the named alkyl groups are substituted, the substituent is F);
- Y is O.
- Z is selected from F, Cl, Br, I; unsubstituted and substituted C1-C2 alkyl, and wherein the named alkyl groups can be substituted by F (i.e. in case the named alkyl groups are substituted, the substituent is F);
- R6 is selected from: OR7, NR8R9;
- R7 is selected from H and linear and branched C1-C4 alkyl;
- R8 and R9 are independently of each other selected from H and linear and branched C1-C4 alkyl.
- In the second most preferred embodiment, the substituents X, R2-R5. Y, Z, and R6-R9 have the same meaning as defined for the first most preferred embodiment, and
- R1 is selected from: linear and branched, unsubstituted and substituted C1-C6 alkyl; substituted and unsubstituted C3-C6 cycloalkyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, cycloalkyl, adamantyl and norbornyl groups can be F (i.e. in case the named groups are substituted, the substituent is F), and wherein the named groups can be single or multiple substituted (i.e. in case the named groups are substituted, they carry one, two or several F).
- Within the above defined first and second most preferred embodiment of the invention, the following embodiments A are preferred in case X is a phenylene ring:
- R1 is selected from: H, linear and branched, unsubstituted and substituted C4, C5 and C6 alkyl; substituted and unsubstituted C4, C5 and C6 cycloalkyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, cycloalkyl, adamantyl and norbornyl groups can be F (i.e. in case the named groups are substituted, the substituent is F), and wherein the named groups can be single or multiple substituted, i.e. the named groups can carry one, two or several F (first preferred embodiment); or R1 is selected from: linear and branched, unsubstituted and substituted C4, C5 and C6 alkyl; substituted and unsubstituted C4, C5 and C6 cycloalkyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, cycloalkyl, adamantyl and norbornyl groups can be F (i.e. in case the named groups are substituted, the substituent is F), and wherein the named groups can be single or multiple substituted (i.e. the named groups can carry one, two or several F) (second preferred embodiment).
- In further embodiments within the above defined first and second most preferred embodiment, the following embodiments B are preferred in case X is a phenylene ring:
- In further embodiments within the above defined most general embodiment, the following embodiments B are preferred in case X is a phenylene ring:
- B1: the phenylene ring X is not substituted, or monosubstituted (i.e. contains 0 or 1 substituent Z other than H); and/or
- B2: the phenylene ring X is not substituted by I (substituent Z) in
position - B3: the phenylene ring X is not substituted by Br (substituent Z) in
position - B4: the phenylene ring X is not substituted by F, Cl, Br or I (substituent Z) in
position - B5: the phenylene ring X is not substituted by I (substituent Z); and/or
- B6: the phenylene ring X is not substituted by F, Cl, Br or I (substituent Z); and/or
- B6: the phenylene ring X is not substituted by —CH3 (substituent Z) in
position - B7: the phenylene ring X is not substituted by —CH3, —C2H5, C3H7 and/or C4H9 (substituent Z) in
position - B8: the phenylene ring Xis not substituted by —CH3, —C2H5, C3H7 and/or C4H9.
- The preferred embodimemts cited above within the first and second most preferred embodiment also comprise the combination of embodiment A with each of the embodiments B1, B2, B3, B4, B5, B6, B7 and B8.
- It has proved advantageous in case X is a phenylene ring, if R1 is a higher noncyclic or cyclic aliphatic group, starting from C4, i.e. if R1 is a group selected from those which have been cited beforehand within the embodiments A.
- In another preferred embodiment of the present invention, R1 is selected from: H; linear and branched, unsubstituted and substituted C1-C6 alkyl, preferably linear and branched, substituted an unsubstituted C1-C5 alkyl; substituted and unsubstituted C3-C6 cycloalkyl; adamantanyl and norbornyl; and wherein the named alkyl, cycloalkyl, adamantanyl and norbornyl groups can be substituted by F (i.e. in case the named groups are substituted, the substituent is F), and wherein the named groups can be single or multiple substituted (i.e. the named groups can carry one, two or several F), and R2-R5, X, Y, Z, R6, R7, and R8 and R9 have the meanings as defined in the general, the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiments. Within the above defined preferred embodiment of the invention, the following embodiments A are preferred in case X is a phenylene ring:
- R1 is selected from: H, linear and branched, unsubstituted and substituted C4, C5 and C6 alkyl; substituted and unsubstituted C4, C5 and C6 cycloalkyl, preferably C5 and C6 cycloalkyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, cycloalkyl, adamantyl and norbornyl groups can be F (i.e. in case the named groups are substituted, the substituent is F), and wherein the named groups can be single or multiple substituted (i.e. the named groups can carry one, two or several F); and R2-R5, X, Y, Z, R6, R7, and R8 and R9 have the meanings as defined in the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiments; wherein the substituents and substitution patterns for the phenylene ring X are as set forth in the embodiments B1, B2, B3, B4, B5, B6 and B7.
- The present preferred embodimemts cited above also comprise the combination of embodiment A with each of the embodiments B1, B2, B3, B4, B5, B6, B7 and B8.
- It has proved advantageous in case X is a phenylene ring, if R1 is a higher noncyclic or cyclic aliphatic group, starting from C4, i.e. if R1 is a group selected from those which have been cited beforehand within the embodiments A.
- In another preferred embodiment of the present invention, R1 is selected from: linear and branched, unsubstituted and substituted C1-C6 alkyl, preferably linear and branched, substituted an unsubstituted C1-C6 alkyl; substituted and unsubstituted C3-C6 cycloalkyl; adamantanyl and norbornyl; and wherein the named alkyl, cycloalkyl, adamantanyl and norbornyl groups can be substituted by F (i.e. in case the named groups are substituted, the substituent is F), and wherein the named groups can be single or multiple substituted (i.e. the named groups can carry one, two or several F), and R2-R5, X, Y, Z, R6, R7, and R8 and R9 have the meanings as defined in the general, the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiments. Within the above defined preferred embodiment of the invention, the following embodiments A are preferred in case X is a phenylene ring:
- R1 is selected from: linear and branched, unsubstituted and substituted C4, C5 and C6 alkyl; substituted and unsubstituted C4, C5 and C6 cycloalkyl, preferably C5 and C6 cycloalkyl; adamantyl and norbornyl; and wherein the substituents of the named alkyl, cycloalkyl, adamantyl and norbornyl groups can be F (i.e. in case the named groups are substituted, the substituent is F), and wherein the named groups can be single or multiple substituted (i.e. the named groups can carry one, two or several F); and R2-R5, X, Y, Z, R6, R7, and R8 and R9 have the meanings as defined in the general, the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiments; wherein the substituents and substitution patterns for the phenylene ring X are as set forth in the embodiments B1, B2, B3, B4, B5, B6 and B7.
- The present preferred embodimemts cited above also comprise the combination of embodiment A with each of the embodiments B1, B2, B3, B4, B5, B6, B7 and B8.
- It has proved advantageous in case X is a phenylene ring, if R1 is a higher noncyclic or cyclic aliphatic group, starting from C4, i.e. if R1 is a group selected from those which have been cited beforehand within the embodiments A.
- In another preferred embodiment of the present invention, R1 is a group selected from —C(CH3)3, —C(CH3)2C2H5, cyclohexyl and adamantanyl, and R2-R5, X, Y, Z, R6, R7, and R8 and R9 have the meanings as defined in the general, the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiment, including the definitions for the case that X is a substituted or non substituted phenylene group.
- In another preferred embodiment of the present invention, the carbonyl derived group —C(Y)R6 connected to the aromatic ring is in position 4 with respect to the ether bridge, and R1, R2-R5, X, Y, Z, R6, R7, and R8 and R9 have the meanings as defined in the general, the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiment, including the definitions for the case that X is a substituted or non substituted phenylene group.
- In another preferred embodiment of the present invention, X is an aromatic cycle selected from a phenylene ring C6H4 , in which one or more H atoms are optionally replaced independently by one or more of the substituents Z; or X is a 6-membered aromatic heterocycle containing 1 N atom, in which one or more H atoms are optionally replaced independently by one or more of the substituents Z; and R1, R2-R5, X, Y, Z, R6, R7, and R8 and R9 have the meanings as defined in the general, the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiment, including the definitions for the case that X is a substituted or non substituted phenylene group.
- In another preferred embodiment of the present invention, X is an aromatic cycle selected from a phenylene ring C6H4 , in which one or more H atoms are optionally replaced independently by one or more of the substituents Z; or X is a 6-membered aromatic heterocycle containing 1 N atom in
position 2 with respect to the ether bridge, in which one or more H atoms are optionally replaced independently by one or more of the substituents Z; and R1, R2-R5, X, Y, Z, R6, R7, and R8 and R9 have the meanings as defined in the general, the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiments, including the definitions for the case that X is a substituted or non substituted phenylene group. - In a further preferred embodiment of the present invention, if X is a phenlyene group, at least one of R2-R5 and Z is a substituent other than H, in case R1 is H or CH3. This applies for the general, the preferred, the more preferred, the even more preferred, the first most preferred or the second most preferred embodiments of the invention
- The term “individual” as used in the context of the present application includes any kind of animals, preferably mammals, and even more preferred humans.
- Preferred compounds according to the present invention showing Notch signaling enhancing activities are depicted below. As the case may be, each compound may fall into the group of the general compounds of the invention as defined in connection with the general formula I, or into the group of preferred compounds, more preferred compounds, even more preferred compounds, first most preferred or second most preferred compounds as defined beforehand.
-
- Journal of Materials Chemistry C: Materials for Optical and Electronic Devices (2013), 1 (34), 5315-5321, Hachisuga et al.: “Flying-seed-like liquid crystals 3: new guideline for the induction of mesomorphism by using bulky groups instead of long alkyl chains”.
- Jpn. Kokai Tokkyo Koho (2012), JP 2012056851 A 20120322, Ito et al.: “Photochemical preparation of aromatic carboxylic acids from aromatic compounds using anthraquinone compounds”.
-
- WO 93/24442, PCT/JP93/00710: “Medicine containing benzoic acid derivative as testosterone 5 -reductase inhibitor and novel benzoic acid derivative”.
- The present invention also relates to a compound showing the general formula (I) and/or a pharmaceutically acceptable salt or ester thereof, in all preferred, more preferred, even more preferred, first most preferred and second most preferred embodiments, and of the individual compounds depicted above, for enhancing Notch signaling in an individual.
- In a further embodiment of the invention, it relates to the compounds as defined in connection with formula (I) and/or a pharmaceutically acceptable salt or ester thereof, including all preferred, more preferred, even more preferred, first most preferred and second most preferred embodiments, and of the individual compounds depicted above, for the treatment of a disease associated with reduced Notch signaling activity.
- The present invention also comprises a method of treating a disease in an individual, comprising administering a compound showing the general formula (I) and/or a pharmaceutically acceptable salt or ester thereof, in all general, preferred, more preferred, even more preferred, first most preferred and second most preferred embodiments, and of the individual compounds depicted above, to the individual.
- The diseases which can be treated with the compounds of the invention include diseases selected from the group of dermatological disorders including atopic dermatitis, psoriasis, immune related disorders, cancer including but not limited to squamous cell carcinoma, for example cutaneous and lung squamous cell carcinoma, head and neck cancer, non-melanoma skin cancer, basal cell carcinoma and actinic keratosis, neuroendocrine tumors, for example neuroendocrine small cell carcinoma and carcinoid tumors, thyroid carcinomas; and muscular disorders including muscular dystrophy and impaired regeneration capacity after injury; and the compounds of the invention can be used in immunotherapy for cancer.
- In the context of the present application, the term “impaired regeneration after injury” preferably relates to muscle injury caused by: diseases such as muscle dystrophy; exposure to myotoxic agents, such as hypivacaine or lidocaine; sharp or blunt trauma, such as punctures or contusions; ischemia; exposure to hot or cold temperatures; the muscle's own contraction, for example in exercise-induced muscle damage and regeneration, in particular following eccentric exercise.
- Diseases which are preferably treated by the compounds of the invention include atopic dermatitis, psoriasis, squamous cell carcinoma, for example cutaneous and lung squamous cell carcinoma, non-melanoma skin cancer, head and neck cancer, basal cell carcinoma and actinic keratosis.
- Diseases which are most preferably treated by the compounds of the invention include immune related disorders.
- In a further most preferred embodiment of the invention, the compounds are used in immunotherapy for cancer.
- Within the teachings of the present invention, the diseases named above in the general, preferred and most preferred embodiments are caused by low Notch signaling and can thus be treated by administering the compounds according to the invention. Preferably, the compounds of the invention are not used for treating prostate cancer (prostate carcinoma), in particular in case X is a phenylene ring.
- In a further embodiment of the invention, it relates to the compounds as defined in connection with formula (I)) and/or a pharmaceutically acceptable salt or ester thereof, including all preferred, more preferred, even more preferred, first most preferred and second most preferred embodiments, and of the individual compounds depicted above, for the treatment of a disease selected from the group of dermatological disorders including atopic dermatitis, psoriasis, immune related disorders, cancer including but not limited to squamous cell carcinoma, for example cutaneous and lung squamous cell carcinoma, head and neck cancer, non-melanoma skin cancer, basal cell carcinoma and actinic keratosis; neuroendocrine tumors, for example neuroendocrine small cell carcinoma and carcinoid tumors, and thyroid carcinomas, muscular disorders including muscular dystrophy and impaired regeneration capacity after injury, as well as for the use in immunotherapy for cancer. Preferably, the invention does not relate to the cited compounds for the treatment of prostate cancer (prostate carcinoma), in particular in case X is a phenylene ring.
- Diseases which are preferably treated by the compounds of the invention include atopic dermatitis, psoriasis, squamous cell carcinoma, for example cutaneous and lung squamous cell carcinoma, non-melanoma skin cancer, head and neck cancer, basal cell carcinoma and actinic keratosis.
- Diseases which are most preferably treated by the compounds of the invention include immune related disorders.
- In a further most preferred embodiment of the invention, the compounds are used in immunotherapy for cancer.
- The present invention also relates to the compounds as defined in connection with formula (I) and/or a pharmaceutically acceptable salt or ester thereof, including all preferred, more preferred, even more preferred, first most preferred and second most preferred embodiments, and of the individual compounds depicted above, for use as a medicament, except for those compounds of which it is known that they can be used as a medicament (pharmaceutical activity) is known.
- Compounds which are described in the art as having a physiological activity are the compounds of formula (Ia) wherein all of R2-R5 are H, the phenylene ring is not substituted by Z, —C(Y)R6 is in position 4 with respect to the ether bridge, Y is O, R6 is OR7, R7 is H, and R1 is H or CH3. These compounds are disclosed in US 2004/0180889, in the context of the treatment of a Pin-1 associated disease including several cancer diseases. No physiological activity for these compounds is shown in the application.
- Further compounds according to formula (I) known to have a pharmaceutical activity are the compounds of formula (Ia) wherein all of R2-R5 are H, the phenylene ring is not substituted by Z, —C(Y)R6 is in position 4 with respect to the ether bridge, Y is O, R6 is OR7, R7 is H,and R1 is i-propyl or cyclohexyl; and compounds of formula (Ia) wherein all of R2-R5 are H, the phenylene ring is substituted by CI (substituent Z) in
position 2 with respect to the ether bridge, —C(Y)R6 is in position 4 with respect to the ether bridge, Y is O, R6 is OR7, R7 is H, and R1 is H, i-propyl or norbornyl; and the compound of formula (Ia) wherein all of R2-R5 are H, the phenylene ring is substituted by F (substituent Z) inposition 2 with respect to the ether bridge, —C(Y)R6 is in position 4 with respect to the ether bridge, Y is O, R6 is OR7, R7 is H, and R1 is methyl. The above compounds (which include compound V169 as mentioned in the present application) are described in WO 93/24442 as testosterone 5-reductase inhibitors and can, inter alia, be used for the treatment of prostate cancer (prostate carcinoma). - Still, the present invention also relates to the compounds as defined in connection with formula (I), including all preferred, more prefered, even more preferred, first most preferred and second most preferred embodiments as such. Compounds which are known as such are not an embodiment of the present invention.
- Compounds which are known as such are compounds V058, V119, V124, V126, V128, V134. V142, V151, and V169.
- Still further compounds according to formula (I) known as such are the compounds of formula (Ia) wherein all of R2-R5 are H, the phenylene ring is not substituted by Z, —C(Y)R6 is in position 4 with respect to the ether bridge, Y is O, R6 is OR7, R7 is H, and R1 is i-propyl or cyclohexyl; and compounds of formula (Ia) wherein all of R2-R5 are H, the phenylene ring is substituted by CI (substituent Z) in
position 2 with respect to the ether bridge, —C(Y)R6 is in position 4 with respect to the ether bridge, Y is O, R6 is OR7, R7 is H, and R1 is H, i-propyl or norbornyl; and the compound of formula (Ia) wherein all of R2-R5 are H, the phenylene ring is substituted by F (substituent Z) inposition 2 with respect to the ether bridge, —C(Y)R6 is in position 4 with respect to the ether bridge, Y is O, R6 is OR7, R7 is H, and R1 is methyl. The above compounds (which include compound V169 as mentioned in the present application) are described in WO 93/24442. - Further compounds which are described in the art as such are the compounds of formula (Ia) wherein all of R2-R5 are H, the phenylene ring is not substituted by Z, —C(Y)R6 is in position 4 with respect to the ether bridge, Y is O, R6 is OR7, R7 is H, and R1 is H or CH3. These compounds are disclosed in US 2004/0180889.
- The present invention also relates to the compounds as defined in connection with formula (I) and/or a pharmaceutically acceptable salt or ester thereof, including all general, preferred, more preferred, even more preferred, first most preferred and second most preferred embodiments, and of the individual compounds depicted above, for use as a medicament in combination therapy, wherein the said compounds are administered in combination with another method of treatment including but not limited to surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy. The present invention also comprises the use of these above defined compounds in combination therapy for the treatment of for the treatment of a disease selected from the group of dermatological disorders including atopic dermatitis, psoriasis, immune related disorders, cancer including but not limited to squamous cell carcinoma, for example cutaneous and lung squamous cell carcinoma, head and neck cancer, non-melanoma skin cancer, basal cell carcinoma and actinic keratosis; neuroendocrine tumors, for example neuroendocrine small cell carcinoma and carcinoid tumors, and thyroid carcinomas, muscular disorders including muscular dystrophy and impaired regeneration capacity after injury, as well as for the use in immunotherapy for cancer. Preferably, the invention does not relate to the cited compounds for the treatment of prostate cancer (prostate carcinoma), in particular in case X is a phenylene ring.
- The term “combination therapy” includes both the sequential and the simultaneous combination of treatments.
- The compounds can be used for enhancing Notch signaling, as et forth below.
- The Notch receptor is synthesized as a 300 kDa precursor that is cleaved by furin-like convertase(s) in the trans-Golgi compartment. The resulting extracellular/lumenal N-terminal fragment and transmembrane domain/intracellular domain C-terminal fragment are assembled into the mature heterodimer receptor through a noncovalent linkage. The extracellular/lumenal portion of Notch undergoes extensive N- and O-linked glycosylation during Notch synthesis and secretion, which is critical for proper folding of the receptor and its subsequent interactions with ligands. Following export to the cell surface, Notch signal transduction is initiated by ligand binding and endocytosis, which generate the forces needed to expose an otherwise inaccessible ADAM10/TACE/Kuz/SUP-17 cleavage site in the extracellular portion of the Notch C-terminal fragment. Cleavage at this site produces the activated, membrane-anchored Notch form termed Notch extracellular truncation (NEXT). NEXT is subsequently cleaved by the intramembrane aspartyl protease complex y-secretase, leading to release of the Notch intracellular signal-transducing fragment termed Notch intracellular domain (NICD). This cleavage can occur at the cell surface and within the endosomal trafficking pathway. In the absence of NICD, most Notch target genes are maintained in an actively repressed state through the formation of transcriptional complexes involving CSL transcription factors and various corepressors (CoRep). Upon nuclear translocation of NICD, corepressors associated with CSL are displaced and a transcriptionally active complex consisting of CSL, NICD, Mastermind (Mam), and coactivators (CoAct) assembles, leading to activation of Notch target genes.
- This schematic presents a simplified overview of the main conserved features of Notch synthesis and signaling; details of the biochemical mechanisms involved are omitted for the sake of clarity, the positions of the Notch diagrams are not intended to accurately depict the topology of Notch in various membrane compartments, and the glycosylation symbols and transcriptional complex diagrams are illustrative and do not imply specific glycosylation site locations or protein-protein interactions.
- Without wishing to be bound by this theory, it is supposed that the compounds of the invention having Notch signaling enhancing properties stabilize the complex CSL-NICD, resulting in an activation of the Notch target genes.
- In case of a pathological condition (i.e. in case the individual suffers from a disease as mentioned herein), the administration of a Notch signaling enhancing compound according to the invention leads to either a normalization of the level of the Notch target genes (as found in healthy individuals), or even to a level higher than that found in healthy individuals,
- As used herein, the term “enhancing Notch signaling” refers to an effect on a cellular Notch-driven luciferase reporter assay, by which the Notch signaling enhancing properties of the compounds of the invention are determined. The Notch-driven luciferase reporter assay consists of HeLa cells engineered to express the Notch1 full length receptor, and to harbor a CSL-driven firefly luciferase expression construct as well as a Notch independent Renilla luciferase construct for the purpose of normalisation. These cells are co-cultured with engineered HeLa cells expressing the Notch ligand DII4 to induce Notch signaling, thus to induce the expression of the firefly luciferase enzyme. The intensity of a luciferase-driven reporter signal is considered as a measure for Notch signaling.
- A compound is considered as having an effect of enhancing Notch signaling if said compound results relative to DMSO in ≥1.5-fold increase, preferably in ≥2.0-fold increase, more preferably in ≥2.5-fold increase and most preferably in ≥3.0-fold increase of the Luciferase-driven reporter signal in the frame of the named Notch-dependent luciferase reporter assay.
- Although Notch was historically identified as an oncogene, studies within the last decade have also demonstrated the tumor suppressive effects of Notch signaling (Koch and Radtke, 2010) (South et al., 2012). In particular in tissues in which Notch signaling induces differentiation such as the skin, and neuroendocrine organs, Notch functions as a tumor suppressor. Thus activating or increasing Notch signaling in cancers including but not limited to cutaneous and lung squamous cell carcinoma (Wang et al., 2011), head and neck cancer (Agrawal et al., 2011; Stransky et al., 2011), neuroendocrine tumors such as thyroid carcinoma (Yu et al., 2013), or neuroendocrine small cell carcinoma (Sriuranpong et al., 2001) and carcinoid tumors (Greenblatt et al., 2007) will induce differentiation and block growth of cancer cells.
- Some of the compounds of the inventions and/or salts or esters thereof, will exist in different stereoisomeric forms. All of these forms are subjects of the invention.
- Described below are exemplary salts of the compounds according to the invention which are included herein. The list of the different salts stated below is not meant to be complete and limiting.
- Compounds according to the invention which contain one or more acidic groups can be used according to the invention, e.g. as alkali metal salts, alkaline earth metal salts or as ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, e.g. ethylamine, ethanolamine, triethanolamine or amino acids.
- Compounds according to the invention which contain one or more basic groups, i.e. groups which can be protonated, can be present and can be used according to the invention in the form of their addition salts with inorganic or organic acids.
- Compounds according to the invention which contain a carboxylic acid group or a thiocarboxylic acid group can be used according to the invention in the form of the respective ester. Esters are those according to formula (I) in which H of the carboxy or the thiocarboxy group is replaced by an organic residue. Suitable organic residues are known to a person skilled in the art. Preferred organic residues include the following:
- An unsubstituted or at least monosubstituted alkyl, preferably a C1-C10 alkyl, an alkenyl, preferably C2-C10-alkenyl, an alkynyl, preferably C3-C10-alkynyl, and an unsubstituted or at least monosubstituted, saturated or unsaturated, non-aromatic or aromatic ring having 3 to 6 C-atoms, and which may contain in the ring one or more heteroatoms from the group N, S or O, and which heteroatom may be identical or different if more than one heteroatom is present. Said substituents being selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, N, S, O, carboxy, sulphonyl, and the like and which can be further substituted.
- Examples for current aromatic groups include aryl groups, for example phenyl groups, and heteroaryl groups, which aryl and heteroaryl groups may be substituted, preferably by the substituents given above.
- The term “C1-C4-alkyl” refers to methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl and tert.-butyl.
- “C3-7 cycloalkyl” or “C3-7 cycloalkyl ring” means a cyclic alkyl chain having 3-7 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl. Each hydrogen of a cycloalkyl carbon may be replaced by a substituent.
- “Heterocyclyl” or “heterocycle” means a cyclopentane, cyclohexane or cycloheptane ring that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated) wherein at least one carbon atom up to 4 carbon atoms are replaced by a heteroatom selected from the group consisting of sulfur (including —S(O)—, —S(O)2—), oxygen and nitrogen (including ═N(O)—) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom. Examples for a heterocycle include but are not restricted to furan, thiophene, pyrrole, pyrroline, imidazole, imidazoline, pyrazole, pyrazoline, oxazole, oxazoline, isoxazole, isoxazoline, thiazole, thiazoline, isothiazole, isothiazoline, thiadiazole, thiadiazoline, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, sulfolane, pyran, dihydropyran, tetrahydropyran, imidazolidine, pyridine, pyridazine, pyrazine, pyrimidine, piperazine, piperidine, morpholine, tetrazole, triazole, triazolidine, tetrazolidine, azepine or homopiperazine. “Heterocycle” means also azetidine.
- Examples for suitable salts include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, napthalenedisulfonic acid, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfamic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid and other acids known to a person skilled in the art.
- The term “pharmaceutically acceptable” means approved by a regulatory agency such as the EMEA (Europe) and/or the FDA (US) and/or any other national regulatory agency for use in animals, preferably in humans.
- Compounds according to the invention which contain several basic groups can simultaneously form different salts.
- If a compound according to the invention simultaneously contains acidic and basic groups in the molecule, the invention also includes, in addition to the salt forms mentioned, inner salts or betaines.
- The respective salts of the compounds according to the invention can be obtained by customary methods which are known to the person skilled in the art, for example by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts.
- Furthermore, the invention includes all salts of the compounds according to the invention which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts or which might be suitable for studying Notch signaling activity of a compound according of the invention in any suitable manner, such as any suitable in vitro assay.
- The present invention furthermore includes all solvates and tautomers of the compounds according to the invention.
- The present invention furthermore includes derivatives/prodrugs (including the salts thereof) of the compounds according to the invention which contain physiologically tolerable and cleavable groups and which are metabolized in animals, preferably mammals, most preferably humans into a compound according to the invention.
- The present invention furthermore includes the metabolites of the compounds according to the invention.
- The term “metabolites” refers to all molecules derived from any of the compounds according to the invention in a cell or organism, preferably mammal.
- Preferably the term relates to molecules which differ from any molecule which is present in any such cell or organism under physiological conditions
- The structure of the metabolites of the compounds according to the invention will be obvious to any person skilled in the art using the various appropriate methods
- The compounds according to general formula (I) can be prepared according to methods published in the literature or, respectively, analogous methods.
- Methods for the synthesis of the compounds are described e.g., in Houben-Weyl, Methoden der Organischen Chemie (Methods of Organic Chemistry), Thieme-Verlag, Stuttgart, or Organic Reactions, John Wiley & Sons, New York.
- Depending on the circumstances of the individual case, in order to avoid side reactions during the synthesis of a compound of the general formula (I), it can be necessary or advantageous to temporarily block functional groups by introducing protective groups and to deprotect them in a later stage of the synthesis, or introduce functional groups in the form of precursor groups which in a later stage are converted into the desired functional groups. Such synthesis strategies and protective groups and precursor groups which are suitable in an individual case are known to the person skilled in the art.
- If desired, the compounds of the formula (I) can be purified by customary purification procedures, for example by recrystallization or chromatography. The starting compounds for the preparation of the compounds of the formula (I) are commercially available or can be prepared according to or analogously to literature procedures.
- A detailed protocol for the preparation of the compounds of the invention is given further below
- The present invention also relates to a pharmaceutical composition comprising a compound as defined in connection with formula (I), including all preferred, more preferred, even more preferred, first most preferred and second most preferred embodiments, in admixture with an inert carrier, wherein said inert carrier is a pharmaceutical carrier.
- The term “carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, including but not limited to peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered orally. Saline and aqueous dextrose are preferred carriers when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions are preferably employed as liquid carriers for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by E. W. Martin. Such compositions will contain a therapeutically effective amount of the therapeutic, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.
- Furthermore, the invention relates to a method for the preparation of a compound according to the invention comprising the steps of coupling, preferably via SNAr coupling, of substituted phenols with electron-poor aromatic (heteroaromatic) halides. The so-synthesized biaryl ethers are further derivatized by procedures including hydrolysis, esterification and amidation. Compounds can be purified by acid-base extraction, or by column chromatography on silica gel, or precipitation/recrystallization, or by other methods of purification known to a person skilled in the art including preparative thin layer chromatography (TLC) and high performance liquid chromatography (HPLC).
- The compounds according to the invention and their pharmaceutically acceptable salts, optionally in combination with other pharmaceutically active compounds suitable to enhance Notch signaling and/or to treat or prevent the above-cited disease or with any other of the drugs known to a person skilled in the art suitable to enhance Notch signaling and/or treat or prevent these diseases can be administered to animals, preferably to mammals, and in particular humans, as pharmaceuticals by themselves, in mixtures with one another or in the form of pharmaceutical preparations.
- Various delivery systems are known and can be used to administer a compound of the invention for enhancing Notch signaling and/or to treat the diseases cited, e.g. encapsulation in liposomes, microparticles, and microcapsules:
- If not delivered directly to the central nervous system, it is advantageous to select and/or modify methods of administration in such a way as to allow the pharmaceutical compound to cross the blood-brain barrier.
- Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds may be administered by any convenient route, for example by infusion, by bolus injection, by absorption through epithelial or mucocutaneous linings and may be administered together with other biologically active agents.
- Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g. by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.
- In another embodiment, the therapeutic can be delivered in a vesicle, in particular a liposome (Langer (1990) Science 249:1527-1533; Treat et al. (1989) Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler, eds., Liss, New York, 353-365; Lopez-Berestein, ibid., 317-327)
- In yet another embodiment, the therapeutic can be delivered via a controlled release system. In one embodiment, a pump may be used (Sefton (1987) CRC Crit. Ref. Biomed. Eng. 14:201-240; Buchwald et al. (1980) Surgery 88:507-516; Saudek et al. (1989) N. Engl. J. Med. 321:574-579). In another embodiment, polymeric materials can be used (Medical Applications of Controlled Release, Langer and Wise, eds., CRC Press, Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball, eds., Wiley, New York (1984); Ranger and Peppas (1983) Macromol. Sci. Rev. Macromol. Chem. 23:61; Levy et al. (1985) Science 228:190-192; During et al. (1989) Ann. Neurol. 25:351-356; Howard et al. (1989) J. Neurosurg. 71:858-863). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (e.g. Goodson, 1984, In: Medical Applications of Controlled Release, supra, Vol. 2,115-138). Other controlled release systems are discussed in the review by Langer (1990, Science 249:1527-1533).
- In order to select an appropriate way of administration, the person skilled in the art will also consider routes of administration which have been selected for other known drugs which enhance Notch signaling or which are used to treat the above-cited diseases.
- For example, drugs are being taken orally, has been launched both as tablets/liquid and as an i.v.-solution.
- In order to select the appropriate dosage, the person skilled in the art will choose a dosage which has been shown to be not toxic in preclinical and/or clinical studies and which can be in accordance with the values given beforehand, or which may deviate from these.
- The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for intravenous administration are generally about 20-500 micrograms of active compound per kilogram body weight. Suitable dosage ranges for intranasal administration are generally about 0.01 mg/kg body weight to 1 mg/kg body weight. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
-
- wherein Hal is selected from F and Cl
- A solution of the respective phenol and the benzoate derivative or, respectively, the carboxylic acid derivative of an aromatic 6-membered heterocycle having 1 or 2 N-atoms, as defined in connection with formula (I), or their substituted derivatives in an appropriate solvent, preferably a polar aprotic solvent, most preferably DMSO, and preferably under addition of anhydrous K2CO3 , was stirred at a temperature between 80° C. and 120° C. depending on the substrate until the limiting reactant was fully converted. The reaction was quenched by addition of water, extracted with organic solvent (preferably Et2O, EtOAc and DCM depending on the substrate). The combined organic layers were washed with sat. aqueous NaCl solution, dried over Na2SO4 and evaporated to dryness under reduced pressure. The crude product was purified by flash column chromatography to give the desired biarylether.
- wherein R6 is an alkoxy group, preferably OC2H5
- Hydrolysis of ester: A solution of the respective ester, preferably the ethyl ester in EtOH/0.5 M NaOH was stirred at a temperature between 40° C. and 120° C. depending on the substrate, preferably 80° C. until the complete consumption of the starting materials. The reaction mixture was cooled down to room temperature and then concentrated under reduced pressure. The residue was dissolved in water, acidified, and extracted with an appropriate organic solvent (preferably EtOAC or DCM). The combined organic layers were washed with sat. aqueous NaCl solution, dried over Na2SO4 and evaporated to dryness under reduced pressure. The crude product was purified by column chromatography on silica gel, or by recrystallization to give the desired carboxylic acid.
- wherein R6 is is an alkoxy group, preferably OC2H5
- Amidation of ester: To a sealed tube were added a solution of the respective ester, preferably the ethyl ester and preferably calcium chloride in an appropriate solvent, preferably MeOH and a solution of NH3 in an appropriate solvent, preferably MeOH. The mixture was stirred at a temperature between 40° C. and 120° C. depending on the substrate, preferably 80° C. until the reaction was completed. The reaction mixture was cooled down to room temperature and concentrated under reduced pressure. The residue was resolved in EtOAc and sat. aqueous NH4Cl solution. The aqueous phase was extracted with EtOAc. The combined organic layers were washed with sat. aqueous NaCl solution, dried over Na2SO4 and evaporated to dryness under reduced pressure. The crude product was purified by flash column chromatography to give the desired amide.
-
- General procedure A: Ethyl 6-chloronicotinate (840 mg, 4.53 mmol, 1.00 equiv), 4-(tert-butyl)phenol (875 mg, 5.82 mmol, 1.29 equiv) and K2CO3 (958 mg, 6.93 mmol, 1.53 equiv) in DMSO (5 mL) were stirred at 100° C. for 24 h. Purification by column chromatography (EtOAc/
petroleum ether 1/15) gave the desired product as colourless solid (1.23 g, 4.10 mmol, 90%); HRMS (ESI) m/z calcd. for C18H22NO3 + [M+H]+ 300.1594, found: 300.1589; 1H NMR (400 MHz, Chloroform-d) δ 8.88-8.79 (m, 1H), 8.26 (dd, J=8.6, 2.4 Hz, 1H), 7.46-7.39 (m, 2H), 7.13-7.04 (m, 2H), 6.91 (dd, J=8.6, 0.6 Hz, 1H), 4.37 (q, J=7.1 Hz, 2H), 1.38 (t, J=7.1 Hz, 3H), 1.34 (s, 9H). -
- General procedure B: Ethyl 6-(4-(tert-butyl)phenoxy)nicotinate (V042) (1.22 g, 4.08 mmol, 1.00 equiv) in a mixture of EtOH (12 mL) and 0.5 M NaOH (12 mL) was stirred at 80° C. for 2 h. Filtration of the acidified crude product through cotton using DCM gave the pure desired product without further purification as colourless solid (1.10 g, 4.05 mmol, 99%); HRMS (ESI) m/z calcd. for C16H16NO3 − [M−H]− 270.1136, found: 270.1134; 1H NMR (400 MHz, Chloroform-d) δ 11.38 (s, 1H), 8.84 (m, 1H), 8.33-8.30 (m, 1H), 7.45 (d, J=7.9 Hz, 2H), 7.10 (d, J=7.8 Hz, 2H), 6.95 (d, J=8.7 Hz, 1H), 1.35 (s, 9H).
-
- General procedure A: Ethyl 6-chloronicotinate (205 mg, 1.10 mmol, 1.00 equiv), 4-(tert-pentyl)phenol (238 mg, 1.45 mmol, 1.31 equiv) and K2CO3 (240 mg, 1.73 mmol, 1.57 equiv) in DMSO (2 mL) were stirred at 80° C. for 4 days. Purification by column chromatography (EtOAc/petroleum ether 1:20) gave the desired product as colourless oil (332 mg, 1.06 mmol, 96%); HRMS (ESI) m/z calcd. for C19H24NO3 + [M+H]+314.1751, found: 314.1753; 1H NMR (400 MHz, Chloroform-d) δ 8.85 (d, J=2.1 Hz, 1H), 8.25 (dd, J=8.6, 2.4 Hz, 1H), 7.36 (d, J=8.7 Hz, 2H), 7.07 (d, J=8.7 Hz, 2H), 6.89 (d, J=8.6 Hz, 1H), 4.36 (q, J=7.1 Hz, 2H), 1.65 (q, J=7.4 Hz, 2H), 1.37 (t, J=7.1 Hz, 3H), 1.29 (s, 6H), 0.71 (t, J=7.4 Hz, 3H).
-
- General procedure A: Ethyl 6-chloronicotinate (206 mg, 1.11 mmol, 1.00 equiv), 4-cyclohexylphenol (252 mg, 1.43 mmol, 1.29 equiv) and K2CO3 (243 mg, 1.76 mmol, 1.58 equiv) in DMSO (2 mL) were stirred at 80° C. for 4 days. Purification by column chromatography (EtOAc/
petroleum ether 1/20) gave the desired product as colourless solid (333 mg, 1.02 mmol, 92%); HRMS (ESI) m/z calcd. for C20H24NO3 + [M+H]+ 326.1751, found: 326.1757; 1H NMR (400 MHz, Chloroform-d) δ 8.89 (s, 1H), 8.29 (d, J=8.0 Hz, 1H), 7.28 (d, J=7.6 Hz, 2H), 7.10 (d, J=7.6 Hz, 2H), 6.93 (d, J=8.5 Hz, 1H), 4.41 (q, J=6.7 Hz, 2H), 2.59-2.54 (m, 1H), 1.96-1.88 (m, 4H), 1.81-1.77 (m, 1H), 1.51-1.39 (m, 7H), 1.33-1.23 (m, 1H). -
- General procedure B: Ethyl 6-(4-cyclohexylphenoxy)nicotinate (V112) (172 mg, 0.53 mmol, 1.00 equiv) in a mixture of EtOH (15 mL) and 0.5 M NaOH (12 mL) was stirred at 80° C. for 6.5 h. Purification of the acidified crude product by recrystallization from DCM gave the desired product as colourless solid (72 mg, 0.24 mmol, 46%); HRMS (ESI) m/z calcd. for C18H20NO3 + [M+H]+ 298.1438, found: 298.1441; 1H NMR (400 MHz, Chloroform-d) δ 8.92 (d, J=2.1 Hz, 1H), 8.31 (dd, J=8.7, 2.3 Hz, 1H), 7.26 (d, J=8.5 Hz, 2H), 7.08 (d, J=8.5 Hz, 2H), 6.94 (d, J=8.7 Hz, 1H), 2.61-2.47 (m, 1H), 1.9-1.85 (m, 4H), 1.77-1.74 (m, 1H), 1.44-1.35 (m, 4H), 1.32 -1.20 (m, 1H).
-
- General procedure B: Ethyl 6-(4-(tert-pentyl)phenoxy)nicotinate (V111) (203 mg, 0.65 mmol, 1.00 equiv) in a mixture of EtOH (2 mL) and 0.5 M NaOH (2 mL) was stirred at 80° C. for 30 min. Filtration of the acidified crude product through cotton using EtOAc gave the pure desired product without further purification as colourless solid (185 mg, 0.65 mmol, 100%); HRMS (ESI) m/z calcd. for C17H20NO3 + [M+H]+ 286.1438, found: 286.1448; 1H NMR (400 MHz, Chloroform-d) δ 8.64 (m, 1H), 8.17-8.06 (m, 1H), 7.22 (d, J=8.3 Hz, 2H), 6.91 (d, J=8.3 Hz, 2H), 6.66 (d, J=8.6 Hz, 1H), 1.51 (q, J=7.4 Hz, 2H), 1.15 (s, 6H), 0.57 (t, J=7.4 Hz, 3H).
-
- General procedure A: Ethyl 4-fluorobenzoate (808 mg, 4.80 mmol, 1.00 equiv), 4-(tert-butyl)phenol (935 mg, 6.22 mmol, 1.30 equiv) and K2CO3 (2.22 g, 16.05 mmol, 3.34 equiv) in DMSO (5 mL) were stirred at 100° C. for 10 days. Purification by column chromatography (EtOAc/petroleum ether 1:20) gave the desired product as colourless oil (1.01 g, 3.39 mmol, 71%); HRMS (ESI) m/z calcd. for C19H23O3 + [M+H]+ 299.1642, found: 299.1648; 1H NMR (400 MHz, Chloroform-d) δ 8.00 (d, J=8.8 Hz, 2H), 7.39 (d, J=8.7 Hz, 2H), 6.99 (d, J=8.7 Hz, 2H), 6.98 (d, J=8.9 Hz, 2H), 4.36 (q, J=7.1 Hz, 2H), 1.38 (t, J=7.1 Hz, 3H), 1.34 (s, 9H).
-
- General procedure C: Calcium chloride hexahydrate (82 mg, 0.37 mmol, 1.11 equiv) and ethyl 6-(4-(tert-butyl)phenoxy)nicotinate (V042) (101 mg, 0.34 mmol, 1.00 equiv) in MeOH (0.5 mL) together with 7 M NH3 in MeOH (0.5 mL, 3.50 mmol, 10 equiv) were stirred at 80° C. for 21 h. Purification by column chromatography on silica gel (DCM/MeOH 4%) gave the desired product as colourless solid (64 mg, 0.24 mmol, 70%); HRMS (ESI) m/z calcd. for C16H19N2O2 + [M+H]+ 271.1441, found: 271.1456; 1H NMR (400 MHz, Chloroform-d) δ 8.61 (d, J=1.9 Hz, 1H), 8.14 (dd, J=8.6, 2.3 Hz, 1H), 7.42 (d, J=8.6 Hz, 2H), 7.06 (d, J=8.6 Hz, 2H), 6.91 (d, J=8.6 Hz, 1H), 6.32 (s, 2H), 1.33 (s, 9H).
-
- General procedure B: Ethyl 4-(4-(tert-butyl)phenoxy)benzoate (V122) (727 mg, 2.44 mmol, 1.00 equiv) in a mixture of EtOH (7.5 mL) and 0.5 M NaOH (7.5 mL) was stirred at 80° C. for 1 h. Filtration of the acidified crude product through cotton using DCM gave the pure desired product without further purification as colourless solid (614 mg, 2.27 mmol, 93%); HRMS (ESI) m/z calcd. for C17H19O3 + [M+H]+ 271.1329, found: 271.1330; 1H NMR (400 MHz, Chloroform-d) δ 8.07 (d, J=8.8 Hz, 2H), 7.41 (d, J=8.7 Hz, 2H), 7.01 (d, J=8.7 Hz, 2H), 7.01 (d, J=8.8 Hz, 2H), 1.35 (s, 9H).
-
- General procedure A: Ethyl 6-chloronicotinate (207 mg, 1.12 mmol, 1.00 equiv), p-cresol (164 mg, 1.52 mmol, 1.36 equiv) and K2CO3 (235 mg, 1.70 mmol, 1.53 equiv) in DMSO (1.5 mL) were stirred at 80° C. for 4 days. Purification by column chromatography (EtOAc/petroleum ether 1:10) gave the desired product as colourless solid (271 mg, 1.05 mmol, 94%); HRMS (ESI) m/z calcd. for C15H16NO3 + [M+H]+ 258.1125, found: 258.1131; 1H NMR (400 MHz, Chloroform-d) δ 8.82 (m, 1H), 8.25 (dd, J=8.6, 2.4 Hz, 1H), 7.21 (d, J=8.2 Hz, 2H), 7.03 (d, J=8.4 Hz, 2H), 6.90 (d, J=8.6 Hz, 1H), 4.37 (q, J=7.1 Hz, 2H), 2.37 (s, 3H), 1.37 (t, J=7.1 Hz, 3H).
-
- General procedure A: Ethyl 6-chloronicotinate (210 mg, 1.13 mmol, 1.00 eq.), 4-(tert-butyl)-2-methylphenol (245 mg, 1.49 mmol, 1.32 equiv) and K2CO3 (247 mg, 1.79 mmol, 1.58 equiv) in DMSO (2 mL) were stirred at 80° C. for 3 days. Purification by column chromatography (EtOAc/petroleum ether 1:20) gave the desired product as colourless oil (259 mg, 0.83 mmol, 73%); HRMS (ESI) m/z calcd. for C19H24NO3 + [M+H]+ 314.1751, found: 314.1759; 1H NMR (400 MHz, Chloroform-d) δ 8.92-8.78 (m, 1H), 8.25 (dd, J=8.7, 2.4 Hz, 1H), 7.28 (d, J=2.4 Hz, 1H), 7.27-7.23 (m, 1H), 6.99 (d, J=8.3 Hz, 1H), 6.87 (dd, J=8.7, 0.6 Hz, 1H), 4.37 (q, J=7.1 Hz, 2H), 2.15 (s, 3H), 1.37 (t, J=7.1 Hz, 3H), 1.34 (s, 9H).
-
- General procedure B: Ethyl 6-(4-(tert-butyl)-2-methylphenoxy)nicotinate (V131) (160 mg, 0.51 mmol, 1.00 equiv) in a mixture of EtOH (4 mL) and 0.5 M NaOH (2 mL) was stirred at 80° C. for 1.5 h. Filtration of the acidified crude product through cotton using DCM gave the pure desired product without further purification as colourless solid (146 mg, 0.51 mmol, 100%); HRMS (ESI) m/z calcd. for C17H20NO3 + [M+H]+ 286.1438, found: 286.1435; 1H NMR (400 MHz, Chloroform-d) δ 9.76 (s, 1H), 8.93 (d, J=2.0 Hz, 1H), 8.31 (dd, J=8.7, 2.4 Hz, 1H), 7.30 (d, J=2.3 Hz, 1H), 7.29-7.25 (m, 1H), 7.01 (d, J=8.3 Hz, 1H), 6.91 (d, J=8.7 Hz, 1H), 2.16 (s, 3H), 1.34 (s, 9H).
-
- General procedure A:
Ethyl 3,4-difluorobenzoate (348 mg, 1.87 mmol, 1.00 equiv), 4-(tert-butyl)phenol (336 mg, 2.24 mmol, 1.20 equiv) and K2CO3 (388 mg, 2.80 mmol, 1.50 equiv) in DMSO (2 mL) were stirred at 100° C. for 22 h. Purification by column chromatography (EtOAc/petroleum ether 1/40) gave the desired product as colourless oil (451 mg, 1.43 mmol, 76%); HRMS (ESI) m/z calcd. for C19H22O3F+ [M+H]+ 317.1547, found: 317.1549; 1H NMR (400 MHz, Chloroform-d) δ 7.85 (dd, J=11.2, 2.0 Hz, 1H), 7.80-7.73 (m, 1H), 7.42-7.35 (m, 2H), 7.02-6.94 (m, 3H), 4.37 (q, J=7.1 Hz, 2H), 1.39 (t, J=7.1 Hz, 3H), 1.33 (s, 9H). -
- General procedure B: Ethyl 4-(4-(tert-butyl)phenoxy)-3-fluorobenzoate (V138) (341 mg, 1.08 mmol, 1.00 equiv) in a mixture of EtOH (3 mL) and 0.5 M NaOH (2 mL) was stirred at 80° C. for 1.5 h. Purification of the acidified crude product by column chromatography (DCM/MeOH 5%) gave the desired product as colourless solid (207 mg, 0.72 mmol, 67%); HRMS (ESI) m/z calcd. for C17H16O3F− [M−H]− 287.1089, found: 287.1084; 1H NMR (400 MHz, Chloroform-d) δ 7.91 (dd, J=11.0, 2.0 Hz, 1H), 7.86-7.79 (m, 1H), 7.47-7.37 (m, 2H), 7.05-6.99 (m, 2H), 6.96 (t, J=8.3 Hz, 1H), 1.34 (s, 9H).
-
- General procedure A: Ethyl 4-fluorobenzoate (308 mg, 1.83 mmol, 1.00 equiv), 4-(tert-pentyl)phenol (380 mg, 2.32 mmol, 1.26 equiv) and K2CO3 (383 mg, 2.77 mmol, 1.51 equiv) in DMSO (4 mL) were stirred at 80° C. for 1 day and then at 120° C. for 2 days. Purification by column chromatography (EtOAc/petroleum ether 1:20) gave the desired product as colourless oil (476 mg, 1.52 mmol, 83%); HRMS (ESI) m/z calcd. for C20H25O3 + [M+H]+ 313.1798, found: 313.1808; 1H NMR (400 MHz, Chloroform-d) δ 8.06-7.98 (m, 2H), 7.37-7.30 (m, 2H), 7.02-6.99 (m, 2H), 6.99-6.96 (m, 2H), 4.36 (q, J=7.1 Hz, 2H), 1.65 (q, J=7.4 Hz, 2H), 1.38 (t, J=7.1 Hz, 3H), 1.30 (s, 9H), 0.71 (t, J=7.4 Hz, 3H).
-
- General procedure A: Ethyl 4-fluorobenzoate (311 mg, 1.85 mmol, 1.00 equiv), 4-((3r,5r,7r)-adamantan-1-yl)phenol (522 mg, 2.29 mmol, 1.24 equiv) and K2CO3 (394 mg, 2.85 mmol, 1.54 equiv) in DMSO (4 mL) were stirred at 80° C. for 1 day and then at 120° C. for 2 days. Purification by column chromatography (EtOAc/petroleum ether 1:20) gave the desired product as colourless solid (551 mg, 1.46 mmol, 79%); HRMS (ESI) m/z calcd. for C25H29O3 + [M+H]+ 377.2111, found: 377.2122; 1H NMR (400 MHz, Chloroform-d) δ 8.06-7.98 (m, 2H), 7.40-7.33 (m, 2H), 7.03-6.99 (m, 2H), 7.00-6.96 (m, 2H), 4.37 (q, J=7.1 Hz, 2H), 2.12 (m, 3H), 1.93 (m, 6H), 1.83-1.75 (m, 6H), 1.39 (t, J=7.1 Hz, 3H).
-
- General procedure B: Ethyl 4-(4-(tert-pentyl)phenoxy)benzoate (V149) (265 mg, 0.85 mmol, 1.00 equiv) in a mixture of EtOH (2.5 mL) and 0.5 M NaOH (2.5 mL) was stirred at 80° C. for 9 h. Purification of the acidified crude product by recrystallization from EtOAc gave the desired product as colourless solid (210 mg, 0.74 mmol, 87%); HRMS (ESI) m/z calcd. for C18H19O3 − [M−H]− 283.1340, found: 283.1343; 1H NMR (400 MHz, Chloroform-d) δ 8.12-8.01 (m, 2H), 7.39-7.31 (m, 2H), 7.03-7.01 (m, 2H), 7.01-6.98 (m, 2H), 1.66 (q, J=7.4 Hz, 2H), 1.31 (s, 9H), 0.71 (t, J=7.4 Hz, 3H).
-
- General procedure B: Ethyl 4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)benzoate (V150) (314 mg, 0.83 mmol, 1.00 equiv) in a mixture of EtOH (2.5 mL) and 0.5 M NaOH (2.5 mL) was stirred at 80° C. for 1 day. Purification of the acidified crude product by recrystallization from EtOAc gave the desired product as colourless solid (227 mg, 0.65 mmol, 78%); HRMS (ESI) m/z calcd. for C23H23O3 − [M−H]− 347.1653, found: 347.1648; 1H NMR (400 MHz, Chloroform-d) δ 8.06-8.03 (m, 2H), 7.40-7.36 (m, 2H), 7.04-7.01 (m, 2H), 7.01-6.98 (m, 2H), 2.11 (m, 3H), 1.93 (m, 6H), 1.78 (m, 6H).
-
- General procedure A: Ethyl 4-fluorobenzoate (316 mg, 1.88 mmol, 1.00 equiv), 4-cyclohexylphenol (412 mg, 2.34 mmol, 1.24 equiv) and K2CO3 (418 mg, 3.03 mmol, 1.61 eq.) in DMSO (4 mL) were stirred at 120° C. for 2 days. Purification by column chromatography (EtOAc/
petroleum ether 1/20) gave the desired product as colourless oil (483 mg, 1.49 mmol, 79%); HRMS (ESI) m/z calcd. for C21H25O3 + [M+H]+ 325.1798, found: 325.1801; 1H NMR (400 MHz, Chloroform-d) δ 8.07-7.96 (m, 2H), 7.23-7.20 (m, 2H), 7.00-6.96 (m, 4H), 4.36 (q, J=7.1 Hz, 2H), 2.54-2.49 (m, 1H), 1.96-1.80 (m, 4H), 1.80-1.72 (m, 1H), 1.47-1.37 (m, 4H), 1.38 (t, J=7.1 Hz, 3H), 1.31-1.21 (m, 1H). -
- General procedure B: Ethyl 4-(4-cyclohexylphenoxy)benzoate (V168) (236 mg, 0.73 mmol, 1.00 equiv) in a mixture of EtOH (3 mL) and 0.5 M NaOH (3 mL) was stirred at 80° C. for 5 h. Purification of the acidified crude product by recrystallization from EtOAc gave the desired product as colourless solid (158 mg, 0.53 mmol, 73%); HRMS (ESI) m/z calcd. for C19H19O3 − [M−H]− 295.1340, found: 295.1339; 1H NMR (400 MHz, Chloroform-d) δ 8.06 (d, J=8.8 Hz, 1H), 7.23 (d, J=8.5 Hz, 2H), 7.24-6.98 (m, 4H), 2.55-2.49 (m, 1H), 1.91-1.85 (m, 4H), 1.78-1.75 (m, 1H), 1.47-1.35 (m, 4H), 1.31-1.21 (m, 1H).
- The respective Notch signaling-enhancing activities of the preferred molecules depicted above in a Notchl-driven luciferase assay are illustrated in
FIG. 1 . A brief description of this Notch reporter assay is given in the caption ofFIG. 1 . Derivative V126 was tested as representative compound in further experiments. -
FIG. 2 shows investigations using V126 in different settings within the luciferase reporter assay. V126 strongly enhanced Notch signaling already at a concentration of 1⇄M, whereas the reported Notch enhancer valproic acid did not show any effect within the frame of the screened concentrations of up to 40⇄M (FIG. 2a ). To rule out that V126 is directly enhancing the activity of the luciferase enzyme, the Notch reporter assay was challenged by applying V126 treatment immediately prior to the readout. Short-term treatment yielded values in the range of the DMSO control level, whereas the corresponding treatment with V126 for 20 h in the very same readout resulted in the expected upregulation of the luciferase values (FIG. 2b ). This strongly suggests that the increased luciferase values are truly derived from enhanced reporter gene expression. Moreover, the Notch-enhancing activity of V126 could be partially and completely rescued by combinational equimolar treatment with the y-secretase inhibitor DAPT or the Notch inhibitor CB103, respectively, further confirming the ability of V126 to upregulate Notch signaling (FIG. 2c ). Testing of V126 in luciferase assays that are driven by the Notch2 receptor isoform (N2FL, Notch2 full-length receptor) or by the truncated, constitutively active form of the Notch1 receptor (N1ICD, Notchl intracellular domain) indicated that V126 is able not only to enhance signaling derived from different Notch receptor isoforms, but also to enhance the signaling cascade taking place downstream of ligand-mediated activation of Notch signaling (FIG. 2d and e). - Notch activation in the skin is known to drive differentiation of keratinocytes resulting in the induction of differentiation markers such as involucrin (C. Nowell, Cold Spring Harb Perspect Med. 2013, 3, 12,), (G. P. Dotto, Oncogene 2008, 27, 5115-5123). Therefore, V126 was further investigated by treatment of the human squamous cell carcinoma cell line SCC13 at a concentration of 10⇄M. Increased expression of involucrin at the protein level was detected upon incubation with V126 for 48 h (
FIG. 3 ), suggesting that V126 is promoting differentiation in this cancer cell line via upregulation of Notch signaling. - In the spleen, marginal zone B-cells (MZBs) and follicular B-cells (FoBs) are the two main types of mature B-cells, both of which develop from the same precursor cells, namely the transitional B-cells (TBs). Notch2 signaling was reported to play a crucial role in the development of MZBs (S. Pillai, Nat. Rev. Immunol. 2009, 9, 767-777) and increased Notch2 signaling in the spleen leads to an expansion of the MZB compartment (F. Hampel, Blood 2011, 118, 24, 6321-6331). In contrast, the development of FoBs is not dependent on Notch signaling. To evaluate the effect of V126 in vivo, C57BL/6N mice were injected intraperitoneally with 25 mg/kg V126 once a day for one week. The impact of V126 on the different B-cell compartments in these mice was analyzed by flow cytometry on splenocytes, showing that V126 was capable to double the number of MZBs as compared to the control, whereas the FoB numbers were not affected (
FIG. 4 ). - In conclusion, these results indicate that V126 is enhancing Notch signaling in vitro and in vivo.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/938,475 US20200360355A1 (en) | 2016-03-17 | 2020-07-24 | Enhancers of notch signaling and their use thereof in the treatment of cancers and malignancies medicable by upregulation of notch |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16160988 | 2016-03-17 | ||
EP16160988.8 | 2016-03-17 | ||
PCT/EP2017/056461 WO2017158190A1 (en) | 2016-03-17 | 2017-03-17 | Enhancers of notch signaling and their use in the treatment of cancers and malignancies medicable by upregulation of notch |
US201816085372A | 2018-09-14 | 2018-09-14 | |
US16/938,475 US20200360355A1 (en) | 2016-03-17 | 2020-07-24 | Enhancers of notch signaling and their use thereof in the treatment of cancers and malignancies medicable by upregulation of notch |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2017/056461 Division WO2017158190A1 (en) | 2016-03-17 | 2017-03-17 | Enhancers of notch signaling and their use in the treatment of cancers and malignancies medicable by upregulation of notch |
US16/085,372 Division US10772876B2 (en) | 2016-03-17 | 2017-03-17 | Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200360355A1 true US20200360355A1 (en) | 2020-11-19 |
Family
ID=55628769
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/085,372 Active US10772876B2 (en) | 2016-03-17 | 2017-03-17 | Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch |
US16/938,475 Pending US20200360355A1 (en) | 2016-03-17 | 2020-07-24 | Enhancers of notch signaling and their use thereof in the treatment of cancers and malignancies medicable by upregulation of notch |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/085,372 Active US10772876B2 (en) | 2016-03-17 | 2017-03-17 | Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch |
Country Status (5)
Country | Link |
---|---|
US (2) | US10772876B2 (en) |
EP (1) | EP3429576A1 (en) |
JP (3) | JP2019513703A (en) |
AU (2) | AU2017232391C1 (en) |
WO (1) | WO2017158190A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3429576A1 (en) * | 2016-03-17 | 2019-01-23 | Xeniopro GmbH | Enhancers of notch signaling and their use in the treatment of cancers and malignancies medicable by upregulation of notch |
US11591289B2 (en) | 2017-02-24 | 2023-02-28 | Xeniopro GmbH | Aromatic compounds |
WO2018154118A2 (en) * | 2017-02-24 | 2018-08-30 | Reinmueller Viktoria | Novel aromatic compounds |
SG11202101307PA (en) * | 2018-08-24 | 2021-03-30 | Xeniopro GmbH | Aromatic molecules for use in the treatment of pathological conditions |
EP3841091A1 (en) * | 2018-08-24 | 2021-06-30 | Xeniopro GmbH | Phenoxy(hetero)aryl ethers of antiproliferative activity |
CN112888479A (en) * | 2018-08-24 | 2021-06-01 | 赛尼欧普罗有限责任公司 | Aromatic molecules for the treatment of pathological conditions |
BR112021018303A2 (en) * | 2019-03-15 | 2021-11-23 | Massachusetts Gen Hospital | Novel small molecule inhibitors of tead transcription factors |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1856880A (en) * | 1931-06-08 | 1932-05-03 | Dow Chemical Co | Esters of salicylic acid |
US20090239860A1 (en) * | 2004-01-28 | 2009-09-24 | Tetsuya Nakamura | Novel benzofuran derivative, medicinal composition containing the same, and uses of these |
US10772876B2 (en) * | 2016-03-17 | 2020-09-15 | Xeniopro GmbH | Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch |
US20220249500A1 (en) * | 2018-08-24 | 2022-08-11 | Xeniopro GmbH | Phenoxy(hetero)aryl ethers of antiproliferactive activity |
US20220354949A1 (en) * | 2018-08-24 | 2022-11-10 | Xeniopro GmbH | Novel compounds |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3113849A (en) * | 1960-06-23 | 1963-12-10 | Dow Chemical Co | Solid gels of liquid hydrocarbons containing salts of alkylphenoxybenzoic acids |
JPH06508621A (en) | 1991-06-12 | 1994-09-29 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | Substituted pyridine herbicides |
GB9116732D0 (en) * | 1991-08-02 | 1991-09-18 | Fujisawa Pharmaceutical Co | Indole derivatives |
WO1993024442A1 (en) | 1992-05-29 | 1993-12-09 | Yamanouchi Pharmaceutical Co., Ltd. | Medicine containing benzoic acid derivative and novel benzoic acid derivative |
WO1994005153A1 (en) | 1992-09-09 | 1994-03-17 | E.I. Du Pont De Nemours And Company | Herbicidal benzene compounds |
JP2001518935A (en) * | 1997-03-26 | 2001-10-16 | バイオソース テクノロジーズ,インコーポレイティド | Di-aryl ethers and their derivatives as anticancer agents |
GB0123587D0 (en) * | 2001-10-01 | 2001-11-21 | Syngenta Ltd | Fungicides |
US20040180889A1 (en) | 2002-03-01 | 2004-09-16 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
JP2012056851A (en) | 2010-09-04 | 2012-03-22 | Nagoya Industrial Science Research Inst | Method for producing aromatic carboxylic acid compound |
WO2013059582A2 (en) | 2011-10-20 | 2013-04-25 | Nupotential, Inc. | Small molecule inhibitors of histone deacteylases |
EP2606884A1 (en) | 2011-12-21 | 2013-06-26 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Inhibitors of notch signaling pathway and use thereof in treatment of cancers |
JP6211530B2 (en) | 2012-11-19 | 2017-10-11 | 武田薬品工業株式会社 | Nitrogen-containing heterocyclic compounds |
-
2017
- 2017-03-17 EP EP17710758.8A patent/EP3429576A1/en active Pending
- 2017-03-17 AU AU2017232391A patent/AU2017232391C1/en active Active
- 2017-03-17 US US16/085,372 patent/US10772876B2/en active Active
- 2017-03-17 WO PCT/EP2017/056461 patent/WO2017158190A1/en active Application Filing
- 2017-03-17 JP JP2018549173A patent/JP2019513703A/en not_active Ceased
-
2020
- 2020-07-24 US US16/938,475 patent/US20200360355A1/en active Pending
-
2022
- 2022-09-06 AU AU2022228099A patent/AU2022228099A1/en not_active Abandoned
- 2022-10-20 JP JP2022168148A patent/JP2023002688A/en active Pending
- 2022-12-02 JP JP2022193285A patent/JP7402300B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1856880A (en) * | 1931-06-08 | 1932-05-03 | Dow Chemical Co | Esters of salicylic acid |
US20090239860A1 (en) * | 2004-01-28 | 2009-09-24 | Tetsuya Nakamura | Novel benzofuran derivative, medicinal composition containing the same, and uses of these |
US10772876B2 (en) * | 2016-03-17 | 2020-09-15 | Xeniopro GmbH | Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch |
US20220249500A1 (en) * | 2018-08-24 | 2022-08-11 | Xeniopro GmbH | Phenoxy(hetero)aryl ethers of antiproliferactive activity |
US20220354949A1 (en) * | 2018-08-24 | 2022-11-10 | Xeniopro GmbH | Novel compounds |
Also Published As
Publication number | Publication date |
---|---|
AU2017232391B2 (en) | 2022-07-14 |
JP2019513703A (en) | 2019-05-30 |
US10772876B2 (en) | 2020-09-15 |
JP2023002688A (en) | 2023-01-10 |
WO2017158190A1 (en) | 2017-09-21 |
JP2023027160A (en) | 2023-03-01 |
AU2017232391A1 (en) | 2018-10-04 |
US20190083476A1 (en) | 2019-03-21 |
AU2017232391C1 (en) | 2022-12-22 |
EP3429576A1 (en) | 2019-01-23 |
JP7402300B2 (en) | 2023-12-20 |
AU2022228099A1 (en) | 2022-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200360355A1 (en) | Enhancers of notch signaling and their use thereof in the treatment of cancers and malignancies medicable by upregulation of notch | |
US7482369B2 (en) | Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors | |
JP2013525458A (en) | Cyclopropyldicarboxamide and analogs exhibiting anticancer and antiproliferative activity | |
TW201443001A (en) | Bicyclic analgesic compounds | |
AU2002351909A1 (en) | Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors | |
WO2019105234A1 (en) | Aromatic compound, pharmaceutical composition thereof and use thereof | |
US20200361872A1 (en) | Substituted halo-quinoline derivatives, method of preparation and applications thereof | |
JP2023538638A (en) | Pyrazole boronic acid compounds, pharmaceutical compositions containing the same, and uses thereof | |
US20100267827A1 (en) | Phenyl-prenyl-ether derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders | |
CA3099739A1 (en) | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | |
WO2023145873A1 (en) | Lysophosphatidylserine analogue, and lysophosphatidylserine analogue-containing phamaceutical composition for treating or preventing fibrosis | |
EP3194360B1 (en) | 4-oxo-n-(4-hydroxyphenyl)retinamide derivatives as therapeutic agents for the treatment of cancer | |
JP2021512861A (en) | Anti-cancer compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |